ADVOCATING FOR CHILDREN AND YOUTH IN RESIDENTIAL

ADVOCATING FOR
CHILDREN AND
YOUTH IN
RESIDENTIAL
TREATMENT CENTERS
Participant Training Manual
Advocating for Children and Youth in Residential Treatment Centers
Participant Training Manual
Table of Contents
List of Residential Treatment Centers in Texas in 2010
Researching Residential Treatment Centers in Texas
Table of Contents for Minimum Standards for General Residential Operations and RTCs
Fact Sheet: Children in Residential Treatment Centers
Top 10 Residential Treatment Center Deficiencies
Checklist: Gathering Information from the Residential Treatment Center
Quick Reference to Psychotropic Medication
Psychotropic Medication Utilization Parameters for Foster Children
Medicaid Managed Care for Foster Children: A Summary of CPPP Report
Residential Treatment for Children and Youth
Treatment Plans for Mental Health
Sample Treatment Plan #1
Sample Treatment Plan #2
Sample Treatment Plan #3
Sample Treatment Plan #4
Developmental, Mental Health/Behavioral and Academic Screens
Advocacy Questions Tree for Provider
Advocating for Children with Emotional Problems
Checklist: Advocating for a child/youth placed in a RTC
Checklist: Advocating for Special Needs
Tips for Providing Experiential Life Skills Training in RTCs
Resources to Aid Caregivers in Providing Experiential Life Skills Training to Foster Youth
A Tip Sheet for Effective Educational Advocacy
A Judicial Checklist for Educational Needs
Tips for Child Advocates
Advocating for Your Child: 25 Tips for Parents
Quick Reference Grid on Information Sharing
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
A Child Is Born
A Child Is Born
A Child is Born
A Fresh Start Treatment Center
A New Day Foundation
Autistic Treatment Center
Autistic Treatment Center, Inc.
AVALON CENTER INC
Azleway Boys Ranch
Bayes Achievement Center
Brookhaven Youth Ranch
Canyon Lakes RTC
Carter's Kids
Center for Success and Independence
Children's Hope Residential Services, Inc.
Daystar Residential Inc.
DePelchin Children's Center-Richmond
Depelchin Childrens Center
Devereux-Houston
Devereux-Victoria
East Texas Open Door
Embracing Destiny Foundation
EVERYDAY LIFE INC
Five Oaks Achievement Center
Good Shepherd
Guardian Angels
Habilitative Homes Inc
Have Haven Inc
Hearts With Hope Foundation
Hector Garza
Helping Hand Home for Children
High Frontier
Hill Country Youth Ranch
HMIH CEDAR CREST, LLC
Hold My Hand
Houston Serenity Place Inc.
Houston Wee Care Shelter Inc
Residential Treatment Centers
Alvin
Alvin
Liverpool
Houston
San Antonio
Dallas
EDDY
TYLER
HUNTSVILLE
West
Lubbock
Houston
Levelland
MANVEL
Richmond
Houston
League City
VICTORIA
MARSHALL
Spring
Bryan
New Ulm
TOMBALL
Houston
San Antonio
Houston
Spring
San Antonio
AUSTIN
Fort Davis
Ingram
BELTON
Houston
Houston
Spring
16111 Nacogdoches Road
10503 Metric Drive
480 HWY 7
15892 CR 26
60 LOWRY LANE
5467 Rogers Hill Rd
2402 Canyon Lakes DR
3722 Pinemont Drive
1313 West Washington Ave
3926 BAHLER
710 South 7th St
123 Shepherd
1150 Devereux Drive
120 David Wade
411& 413 West Burleson
17803 Wood Bark Rd
6955 Broach Road
7674 Pechacek Road
23538 COONS ROAD
9530 West Montgomery
9019 Old Sky Harbor Road
14054 Ambrose
17718 August Meadows Ln.
620 East Afton Oaks
3804 AVENUE B
1173 High Frontier Rd.
3522 Junction Highway
3500 S. IH-35
7722 Glen Vista
6509 Morrow
28915 S Plum Creek
City
2403 FM 2917
7415 Live Oak Circle
6911 CR 171
7809 Winship
Address
HARRIS
HOCKLEY
BRAZORIA
FORT BEND
HARRIS
GALVESTON
VICTORIA
HARRISON
HARRIS
BRAZOS
AUSTIN
HARRIS
HARRIS
BEXAR
HARRIS
HARRIS
BEXAR
TRAVIS
JEFF DAVIS
KERR
BELL
HARRIS
HARRIS
HARRIS
BEXAR
DALLAS
FALLS
SMITH
WALKER
MCLENNAN
LUBBOCK
BRAZORIA
BRAZORIA
BRAZORIA
HARRIS
County
77018
79336
77578
77469
77007
77573
77905
75670
77379
77808
78950
77377
77088
78242
77045
77379
78232
78751
79734
78025
76513
77061
77091
77386
78247
75243
76524
75707
77340
76691
79415
77511
77511
77577
77028
Zip
281-581-2475
281-393-1054
281-581-2704
713-635-1081
281-257-1218
210-590-2107
972-644-2076
254-859-5990
903-566-6827
936-291-3391
254-829-1920
806-762-5782
281-239-6999
713-426-4545
806-897-9735
281-489-0317
281-342-4906
713-861-8136
281-335-1000
361-575-8271
903-935-2099
281-370-6727
979-589-1885
979-992-3791
281-374-0777
281-447-1812
210-623-5419
713-413-9490
281-376-0320
210-568-8600
512-459-3353
432-364-2241
830-367-2131
254-939-2100
713-645-0042
713-691-5572
281-363-4020
Phone
31
15
13
13
13
14
31
32
74
59
71
40
36
44
20
141
20
44
44
85
28
13
44
40
40
24
19
13
14
123
41
84
50
72
13
71
16
Capacity
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
Independence Farm
Juliette Fowler Homes Inc
KCI Servants Heart
Krause Children's Residential
L'Amor Village
Laurel Ridge Treatment Center
Mary Ruth
Meridell Achievement Center
Minolas Place of Texas INC
Minolas Place of Texas INC
Nacogdoches Boy's Ranch
Nelson Childrens Residential Treatment
New Encounters Residential Treatment
New Hope Youth Center
New Horizons Audrey Grace House
New Horizons Ranch
New Life Childrens Treatment Center
Pegasus Schools, Inc.
Positive Steps Inc
Renewed Strength Inc
Roy Maas Youth Alternatives Meadows
San Marcos Treatment Center
Shamar Hope Haven
Sheltering Harbour
Shiloh Treatment Center
Shoreline Inc
Sinclair Children's Center
Southwest Key Program INC
Texas Adolescent Treatment Center
Texas NeuroRehab Center
The Burke Foundation-Pathfinders
The Settlement Club Home
UT Harris County Psychiatric Center
Thompson's Residential Treatment Center
Totally Fit Ministries
Unity Children's Home
Whispering Hills Achievement Center
Willow Bend Center
Youth and Family Enrichment Centers Inc
CORSICANA
Dallas
San Antonio
KATY
HOUSTON
San Antonio
Missouri City
Liberty Hill
Spring
Tomball
NACOGDOCHES
DENTON
CORSICANA
Richmond
Goldthwaite
Canyon Lake
Lockhart
Houston
Houston
Boerne
San Marcos
Houston
Spring
Manvel
Taft
WOODVILLE
HOUSTON
San Antonio
Austin
Driftwood
Austin
Houston
Crosby
Spring
Flatonia
Tyler
TYLER
2715 LIBERTY DRIVE
1220 Abrams Rd
4040 High Ridge Circle
25752 Kingsland Blvd
16540 KUYKENDAHL ROAD
17720 Corporate Woods Dr
16711 Quail View Court
12550 West Hwy. 29
17940 Country Walk
30715 Quinn Rd.
7245 FM 1275
4601 INTERSTATE 35 NORTH
4121 FM ROAD 637
4111 Brandt Rd
850 F M 574 W
650 Scarborough
896 Robin Ranch Rd.
2701 Rosedale
110 Hambrick
121 Old San Antonio Road
120 Bert Brown Road
2719 Truxillo St
17803 W Strack DR
3926 Bahler
1220 Gregory ST
207 NELLIUS STREET
7900 MESA
8550 Huebner
1106 West Dittmar
20800 FM 150 W
1600 Payton Gin Rd
2800 South MacGregor Way
10510 Crosby Lynchburg
2111 River Valley
4110 FM 609
2902 Highway 31 East
14023 Hwy 155 S
HARRIS
HARRIS
FAYETTE
SMITH
SMITH
MILLS
COMAL
CALDWELL
HARRIS
HARRIS
KENDALL
HAYS
HARRIS
HARRIS
BRAZORIA
SAN PATRICIO
TYLER
HARRIS
BEXAR
TRAVIS
HAYS
TRAVIS
HARRIS
NAVARRO
DALLAS
BEXAR
FORT BEND
HARRIS
BEXAR
FORT BEND
WILLIAMSON
HARRIS
HARRIS
NACOGDOCHES
DENTON
NAVARRO
FORT BEND
77532
77373
78941
75702
75711
76844
78133
78644
77004
77060
78006
78666
77004
77379
77578
78390
75979
77028
78240
78745
78619
78758
77021
75110
75214
78229
77494
77068
78259
77489
78642
77379
77375
75965
76207
75109
77469
903-874-2377
214-827-0813
210-212-2500
281-392-7505
281-586-9708
210-491-9400
281-416-7822
512-528-2100
281-251-7696
281-290-8146
936-569-0293
940-484-8232
903-874-1577
281-344-8050
325-437-1852
325-938-5518
830-964-4390
512-376-2101
713-522-0559
281-448-7550
830-816-2425
512-396-8500
713-942-8822
281-251-8686
281-489-1290
361-643-6643
409-283-6800
713-635-8505
210-568-8500
512-444-4835
512-858-4258
512-836-2150
713-741-5000
903-883-5437
281-426-5098
281-355-0716
361-865-3083
903-596-8900
903-534-0414
13
28
36
65
42
62
13
134
13
21
26
65
14
16
14
100
60
175
35
13
48
265
22
65
43
36
35
54
145
36
21
35
20
16
18
48
20
52
54
Researching Residential
Treatment Centers in Texas
On-line information available:
The first step is to use your internet search engine (such as “Google”) to type in the name of
the RTC and find out what you can discover from their own website.
Texas Department of Family and Protective Services:
The second step is to visit the DFPS website to view their record.
Go to: www.dfps.state.tx.us
On the left sidebar, select “Child Care Licensing”
On the left sidebar, select “Search Texas Child Care”
On the full screen, scroll down and select “Search for a Residential (24 hours)
Operation”
On the pull down menu by “Operation Type”, select “Residential Treatment Center”
On the pull down menu for “Issuance Type“, select “full permit”
Now you can search by Name (type in name of the RTC...see your list!), City,
County or a combination of those fields
Referencing Minimum Standards for Residential Treatment Centers:
If you have a particular issue or question, you can refer to the DFPS Minimum Standards for
RTCs.
Go to: www.dfps.state.tx.us
On the left sidebar, select “Child Care Licensing”
On the left sidebar, select “Standards and Regulations”
Scroll down until you see “Minimum Standards for Residential, 24-hour Care
Operations and Child-Placing Agencies”
Select “Chapter 748, Minimum Standard Rules for General Residential Operations
and Residential Treatment Centers”
A Table of Contents is included in your handouts for quick reference
Obtaining information from the RTC:
Finally, since every RTC is different in type, quality and practices, you will need to gather as
much information as you can on your first visit to the RTC.
Licensing Division
Texas Department of Family and Protective Services
MINIMUM STANDARDS
FOR
GENERAL RESIDENTIAL
OPERATIONS AND RESIDENTIAL
TREATMENT CENTERS
Stock Code
XXXX-0000
January 2007
Minimum Standards for General Residential Operations And Residential Treatment Centers
Page v
Minimum Standards for General Residential Operations and
Residential Treatment Centers
Introduction ........................................................................................................................................ ix
Minimum Standards ............................................................................................................... ix
General Residential Operations and Residential Treatment Centers .................................................1
Subchapter A, Purpose and Scope...............................................................................................1
Subchapter B, Definitions and Services........................................................................................3
Division 1, Definitions..............................................................................................................3
Division 2, Services.................................................................................................................8
Subchapter C, Organization and Administration .........................................................................13
Division 1, Permit Holder Responsibilities.............................................................................13
Division 2, Governing Body...................................................................................................16
Division 3, General Fiscal Requirements ..............................................................................17
Division 4, Required Postings ...............................................................................................17
Division 5, Policies and Procedures ......................................................................................19
Subchapter D, Reports and Record Keeping..............................................................................25
Division 1, Reporting Serious Incidents and Other Occurrences ..........................................25
Division 2, Operation Records ..............................................................................................32
Division 3, Personnel Records ..............................................................................................32
Division 4, Child Records ......................................................................................................34
Division 5, Record Retention.................................................................................................35
Subchapter E, Personnel ............................................................................................................37
Division 1, General Requirements ........................................................................................37
Division 2, Child-Care Administrator .....................................................................................39
Division 3, Professional Level Service Providers ..................................................................41
Division 4, Treatment Director...............................................................................................46
Division 5, Caregivers ...........................................................................................................48
Division 6, Contract Staff and Volunteers .............................................................................49
Subchapter F, Training and Professional Development..............................................................53
Division 1, Definitions............................................................................................................53
Division 2, Orientation ...........................................................................................................54
Division 3, Pre-Service Experience and Training ..................................................................54
Division 4, General Pre-Service Training ..............................................................................57
Division 5, Pre-Service Training Regarding Emergency Behavior Intervention ....................58
Division 6, Annual Training ...................................................................................................60
Division 7, First-Aid and CPR Certification............................................................................65
Subchapter G, Child/Caregiver Ratios ........................................................................................67
Subchapter H, Child Rights.........................................................................................................73
Texas Department of Family and Protective Services
January 2007
Page vi
Minimum Standards for General Residential Operations And Residential Treatment Centers
Subchapter I, Admission, Service Planning, and Discharge .......................................................81
Division 1, Admission ............................................................................................................81
Division 2, Emergency Admission .........................................................................................90
Division 3, Educational Services ...........................................................................................92
Division 4, Service Plans.......................................................................................................93
Division 5, Service Plan Reviews and Updates ..................................................................101
Division 6, Discharge and Transfer Planning ......................................................................103
Division 7, Release of Child ................................................................................................106
Subchapter J, Child Care ..........................................................................................................107
Division 1, Dental Care .......................................................................................................107
Division 2, Medical Care .....................................................................................................108
Division 3, Communicable Diseases ...................................................................................112
Division 4, Protective Devices .............................................................................................114
Division 5, Supportive Devices............................................................................................115
Division 6, Tobacco Use .....................................................................................................116
Division 7, Nutrition and Hydration ......................................................................................116
Division 8, Additional Requirements for Infant Care ...........................................................126
Division 9, Additional Requirements for Toddler Care ........................................................130
Division 10, Additional Requirements for Pregnant Children ..............................................132
Subchapter K, Operations That Provide Care for Children and Adults .....................................135
Division 1, Scope ................................................................................................................135
Division 2, General Requirements ......................................................................................135
Subchapter L, Medication .........................................................................................................139
Division 1, Administration of Medication .............................................................................139
Division 2, Self-Administration of Medication ......................................................................141
Division 3, Medication Storage and Destruction .................................................................142
Division 4, Medication Records ...........................................................................................143
Division 5, Medication and Label Errors..............................................................................144
Division 6, Side Effects and Adverse Reactions to Medication ...........................................145
Division 7, Use of Psychotropic Medication ........................................................................146
Subchapter M, Discipline and Punishment ...............................................................................149
Subchapter N, Emergency Behavior Intervention .....................................................................153
Division 1, Definitions..........................................................................................................153
Division 2, Types of Emergency Behavior Intervention That May Be Administered ...........155
Division 3, Orders................................................................................................................158
Division 4, Responsibilities During Administration of Any Type of Emergency Behavior
Intervention........................................................................................................161
Division 5, Additional Responsibilities During Administration of a Personal Restraint ........163
Division 6, Additional Responsibilities During Administration of Seclusion .........................165
January 2007
Texas Department of Family and Protective Services
Minimum Standards for General Residential Operations And Residential Treatment Centers
Page vii
Division 7, Additional Responsibilities During Administration of a Mechanical Restraint ....166
Division 8, Successive Use and Combinations of Emergency Behavior Intervention .........167
Division 9, Time Restrictions for Emergency Behavior Intervention....................................170
Division 10, General Caregiver Responsibilities, Including Documentation, After the
Administration of Emergency Behavior Intervention..........................................173
Division 11, Triggered Reviews...........................................................................................176
Division 12, Overall Operation Evaluation...........................................................................178
Subchapter O, Safety and Emergency Practices......................................................................181
Division 1, Sanitation and Health Practices ........................................................................181
Division 2, Natural Gas and Liquefied Petroleum ...............................................................185
Division 3, Fire Safety Practices .........................................................................................186
Division 4, Heating Devices ................................................................................................190
Division 5, Carbon Monoxide Safety Practices ...................................................................191
Division 6, Emergency Evacuation and Relocation.............................................................192
Division 7, First-Aid Kits ......................................................................................................195
Subchapter P, Physical Site......................................................................................................197
Division 1, Grounds and General Requirements.................................................................197
Division 2, Interior Space ....................................................................................................199
Division 3, Toilet and Bath Facilities ...................................................................................204
Division 4, Poisons..............................................................................................................207
Division 5, Food Preparation, Storage, and Equipment ......................................................207
Division 6, Play Equipment and Safety Requirements ........................................................212
Division 7, Playground Use Zones ......................................................................................215
Division 8, Protective Surfacing ..........................................................................................217
Division 9, Swimming Pools, Wading/Splashing Pools, and Hot Tubs................................218
Subchapter Q, Recreation Activities .........................................................................................221
Division 1, General Requirements ......................................................................................221
Division 2, Swimming Activities ...........................................................................................225
Division 3, Watercraft Activities...........................................................................................228
Division 4, Wilderness Hiking and Camping Excursions .....................................................229
Division 5, Trampoline Use .................................................................................................237
Division 6, Weapons, Firearms, Explosive Materials, and Projectiles.................................238
Subchapter R, Transportation ...................................................................................................241
Division 1, General Requirements ......................................................................................241
Division 2, Safety Restraints ...............................................................................................244
Division 3, Vehicle and Vehicle Maintenance .....................................................................246
Division 4, Transportation Records .....................................................................................246
Subchapter S, Additional Requirements for Operations That Provide
Emergency Care Services.......................................................................................247
Texas Department of Family and Protective Services
January 2007
Page viii
Minimum Standards for General Residential Operations And Residential Treatment Centers
Division 1, Service Management.........................................................................................247
Division 2, Admission Assessment .....................................................................................249
Division 3, Respite Child-Care Services .............................................................................251
Subchapter T, Additional Requirements for Operations That Provide an
Assessment Services Program ...............................................................................253
Division 1, Regulation .........................................................................................................253
Division 2, Admission ..........................................................................................................253
Division 3, Assessment Plan ...............................................................................................254
Division 4, Assessment Report ...........................................................................................255
Subchapter U, Additional Requirements for Operations That Provide Therapeutic Camp
Services...................................................................................................................257
Division 1, Definitions..........................................................................................................257
Division 2, Activities Requiring Spotting or Belaying ...........................................................258
Division 3, Primitive Camping Excursions ...........................................................................259
Index ...............................................................................................................................................263
January 2007
Texas Department of Family and Protective Services
Fact Sheet: Children in Residential
Treatment Centers
I. Tens of thousands of children with mental health needs are being
placed in expensive, inappropriate and often dangerous institutions.
The number of children placed in residential treatment centers (or RTCs)[1] is growing exponentially.[2]
These modern-day orphanages now house more than 50,000 children nationwide.[3] Children are packed
off to RTCs, often sent by officials they have never met, who have probably never spoken to their parents,
teachers or social workers.[4] Once placed, these kids may have no meaningful contact with their families
or friends for up to two years.[5] And, despite many documented cases of neglect and physical and sexual
abuse, monitoring is inadequate to ensure that children are safe, healthy and receiving proper services in
RTCs.[6] By funneling children with mental illnesses into the RTC system, states fail—at enormous
cost—to provide more effective community-based mental health services.[7]
A. RTC placements are often inappropriate.
RTCs are among the most restrictive mental health services and, as such, should be reserved for children
whose dangerous behavior cannot be controlled except in a secure setting.[8] Too often, however, childserving bureaucracies hastily place children in RTCs because they have not made more appropriate
community-based services available.[9] Parents who are desperate to meet their kids’ needs often turn to
RTCs because they lack viable alternatives.[10]
To make placement decisions, families in crisis and overburdened social workers rely on the institutions’
glossy flyers and professional websites with testimonials of saved children.[11] But all RTCs are not
alike.[12] Local, state and national exposés and litigation “regarding the quality of care in residential
treatment centers have shown that some programs promise high-quality treatment but deliver low-quality
custodial care.”[13] As a result, parents and state officials play a dangerous game of Russian roulette as
they decide where to place children, because little public information is available about the RTCs, which
are under-regulated and under-supervised.
To make it worse, far too many children are placed at great distance from their homes. For example, most
District of Columbia children in RTCs are placed outside the District—many as far away as Utah and
Minnesota.[14] Many families, especially those with limited means, find it impossible to have any
meaningful visitation with their children.
B. Evidence is limited on the effectiveness of RTCs.
Children frequently arrive at RTCs traumatized by the process that delivered them there. They are often
forcibly removed from their homes in the middle of the night by “escort companies.”[15] Other times,
children are placed in RTCs not by their parents or doctors, but by overburdened child-serving state
agencies, who know little about the children’s individual needs.[16]
Even more appalling, many children’s conditions do not improve at all while at the RTC.[17] In fact, there
is little evidence that placing children in RTCs has any positive impact at all on their mental health
state[18] and any gains made during a stay in an RTC quickly disappear upon discharge, creating a cycle
where children return again and again to RTCs.[19]
There are many reasons why RTCs fail to deliver the results they promise, but most center on the type of
services provided, the environment they are provided in and the lack of family involvement.
First, the reality of what occurs within an RTC is often quite different from the highly individualized,
highly structured programs that are advertised. The RTCs often provide less intense services and the staff
are often under-trained.[20] Children spend much of their day with staff who are not much more qualified
than the average parent and they spend less time face-to-face with psychiatrists than they would if they
were being served in appropriate community settings.[21]
The environment is also problematic because children in RTCs enter a situation where their only peers are
other troubled children—a major risk factor for later behavioral problems.[22] Research has demonstrated
that some children learn antisocial or bizarre behavior from intensive exposure to other disturbed
children.[23]
Children are usually far from home in RTCs, often out-of-state.[24] Removed from their families and
natural support systems, they are unable to draw upon the strengths of their communities and their
communities are unable to contribute to their treatment. Few children thrive when they are hundreds or
thousands of miles from their parents, friends, grandparents and teachers. Few can flourish without the
guidance of consistent parenting. Yet, we expect that our most vulnerable and troubled youth will
miraculously turn around in just such a situation. Instead, this isolation further reduces the efficacy of
treatment and increases its cost.[25]
The fact that children and their families are far from one another creates a host of problems. For one, it
makes family therapy difficult or impossible. As a result, when children leave the RTC, they return to an
environment that has not changed. Also, because the RTC environment is inherently artificial—children
are not asked to negotiate the obstacles that occur within their family setting or deal with the difficulties
that trigger their behaviors in their neighborhoods or schools—the child does not gain new skills to better
negotiate life outside of an institution. As a result, neither the children nor their parents learn better ways
to overcome the obstacles that led to the RTC placement. Without family involvement, successes are
limited.[26]
Among the rare children who are able to overcome these obstacles, few can sustain the gains they have
made. In one study, nearly 50% of children were readmitted to an RTC, and 75% were either
renstitutionalized or arrested.[27]
C. Children suffer because there is no watchdog.
The RTC industry is largely unregulated.[28] RTCs need only report major unusual incidents (or MUIs),
but the interpretation of what constitutes an MUI and the reporting requirements vary widely.[29] Some
RTCs fail to report MUIs at all—with little consequence.[30] Vulnerable kids are placed far from home
where parents, social workers, or the state can offer little oversight or protection. Worse, many of the
facilities limit children’s ability to have contact with their parents for extended periods, further restricting
the parents’ ability to monitor the facilities.[31]
D. Children are abused in RTCs.
Children placed in RTCs have been sexually and physically abused, restrained for hours, over-medicated
and subject to militaristic punishments; some have died.[32] The following are just a few documented
examples of tragic occurrences at RTCs:
•
•
•
•
•
•
Medication is often used (and overused) to control behavior.[33] Children have been permanently
disfigured because of over-medication.[34]
In some programs, the children’s shoes are confiscated to keep them from running away.[35]
There have been reports of behavioral ‘therapies’ being misused. As one author noted, “Such
therapies do little more than systematically punish children, all under the guise of treatment.”[36]
Sexual abuse by staff members and other residents is all too frequent.[37] In one case, a 13-year
old girl performed sexual favors for staff members in return for snacks and carryout food.[38] At
one RTC, four boys were accused of trying to sodomize another with a cucumber.[39] At another,
a 19-year-old woman was charged with sodomizing a 14-year-old girl.[40]
Physical abuse is also too frequent an occurrence. For example, a 13-year-old boy was forced
against a wall and slammed to the floor by employees of an RTC.[41]
Children are often restrained—sometimes for hours on end. The overuse of restraint has resulted
in child deaths.[42]
E. Tragic outcomes at great public expense.
RTCs have grown to a billion-dollar, largely private industry.[43] Residential treatment care is exorbitantly
expensive—costing up to $700 per child per day.[44] Annual costs can exceed $120,000.[45] Most of the
time, the public foots the bill for these services.[46] In fact, nearly one fourth of the national outlay on
child mental health is spent on care in these settings.[47]
II. Other Interventions Work Better for Less
Home- and community-based services are much more therapeutically effective than institutional services,
and are also markedly more cost-efficient. As the Surgeon General reported, “the most convincing
evidence of effectiveness is for home-based services and therapeutic foster care” and not for RTCs.[48] A
comprehensive system of care would dramatically reduce the number of children in RTCs.[49]
Community-based alternatives produce better short- and long-term results and are less disruptive to
children and families. These alternatives provide intensive mental health treatment, mobilize community
resources and help children and their families develop effective coping mechanisms. Some models
endeavor to “wrap services around” the child, while others emphasize multi-systemic therapy and crisis
intervention. Randomized clinical trials found greater declines in delinquency and behavioral problems,
greater increases in functioning, greater stability in housing placements and greater likelihood of
permanent placement.[50] In Milwaukee, a wraparound project that has served over 700 youth involved in
juvenile justice has shown similar promise; use of residential treatment has declined 60%, use of
psychiatric hospitalization has declined 80%, and average overall care costs for target youth have dropped
by one third.[51]
Notes
[1] According to the Surgeon General, a RTC is a “licensed 24-hour facility (although not licensed as a
hospital), which offers mental health treatment.” U.S. Department of Health and Human Services. 1999.
Mental Health: A Report of the Surgeon General. Washington, DC: Author. Available at:
http://www.surgeongeneral.gov/library/mentalhealth/chapter3/sec7.html#treatment.
[2] In 1982, when Jane Knitzer wrote the seminal book, Unclaimed Children, the growth in the RTC
industry was only beginning. Ms. Knitzer wrote that: “In contrast to the minimal efforts to create
nonresidential services, 18 of the 44 states responding to our survey were working to increase residential
care.” Knitzer, J., Unclaimed Children: The Failure of Public Responsibility to Children and Adolescents
in Need of Mental Health Care, Children’s Defense Fund, 1982, at 45. By 1986, the number of children in
RTCs had grown to 25,334, an increase of more than 30% over a three-year period. Rivera, V.R. &
Kutash, K. (1994), Components of a System of Care. What Does the Research Say?, Residential Services:
Psychiatric Hospitals and Residential Treatment Centers, at 8, Tampa , FL: University of South Florida,
Florida Mental Health Institute: The Research and Training Center for Children’s Mental Health. This
growth in continuing. See infra, at note 3.
[3] Latest Findings in Children’s Mental Health, Nearly 66,000 Youth Live in U.S, Mental Health
Programs, Vo1. 2, No. 1 (Summer 2003). In 1997, the year in which the most recent data was available,
more than 42,000 children were living in RTCs. Given the expansion of children living in RTCs, see
supra note 2, this figure is likely well over 50,000 now.
[4] Reports to staff attorneys at the Bazelon Center for Mental Health Law. For example, in Washington,
D.C., children are certified to go to RTCs by a “Multi-Agency Planning Team” process (or MAPT
process). The MAPT meetings often do not include the voices of the people who know the child and
family best.
[5] Ohio Rights Service Review of Fifteen Children’s Mental Health Facilities (October 2004) (on file
with the Bazelon Center)
[6] See infra at sections I(C) and I(D).
[7] This development of long-term residential care occurred at the expense of community-based
alternatives. Jane Knitzer, as far back as 1982, noted that: “In general, funds were used to develop longterm residential care, with few efforts to support or create emergency shelters, respite care programs, or
specialized foster care for disturbed children and adolescents.” Unclaimed Children, supra note 2, at 46.
Further, the Surgeon General noted that one of the primary reasons that RTCs are considered to be
justified is because community-based alternatives are lacking. See Mental Health: A Report of the
Surgeon General, supra note 1.
[8] Duchnowski, A.J., Hall, K. S., Kutash, K, and Friedman, R. (1998) The Alternatives to Residential
Treatment Study, in Outcomes for Child and Youth with Behavioral and Emotional Disorders and Their
Families. See also Mental Health: A Report of the Surgeon General, supra note 1.
[9] Mental Health: A Report of the Surgeon General, supra note 1, (“Concerns about residential care
primarily relate to criteria for admission . . . .”).
[10] Lou Kilzer, Desperate Measures, Rocky Mountain News, July 2, 1999, available at:
http://www.denver-rmn.com/desperate/site-desperate/front-pg.htm.
[11] Id.
[12] Mental Health: A Report of the Surgeon General, supra note 1, (“Settings range from structured
ones, resembling psychiatric hospitals, to those that are more like group homes or halfway houses.”);
Rivera, V.R. & Kutash, K. (1994), Components of a System of Care. What Does the Research Say?,
Tampa , FL: University of South Florida, Florida Mental Health Institute: The Research and Training
Center for Children’s Mental Health.
[13] Jane Knitzer noted this fact in 1982 in Unclaimed Children, supra note 2, at 46. The calls for reform
have only increased as the population of children served in RTCs has grown. See infra at note 29 and
accompanying text.
[14] Scott Higham and Sewell Chan, District Reexamines Out of Town Centers, The Washington Post,
July 16, 2003, available at: http://www.washingtonpost.com/ac2/wpdyn?pagename=article&contentId=A61386-2003Jul15&notFound=true. See also, D.C. Department of
Mental Health Data from 2003 Children in Residential Treatment Centers (on file at the Bazelon Center).
[15] Kilzer, supra note 10.
[16] Supra, note 4.
[17] Mental Health: A Report of the Surgeon General, supra note 1.
[18] Burns, B.J., Hoagwood, K. & Maultsby, L.T., Improving Outcomes for Children and Adolescents
with Serious Emotional and Behavioral Disorders: Current and Future Directions. (“A dominant
observation is that the least evidence of effectiveness exists for residential services, where the vast
majority of dollars are spent.”); Chamberlain, P. , Treatment Foster Care, US Department of Justice,
Office of Juvenile Justice and Delinquency Prevention, Juvenile Justice Bulletin, December, 1998.
[19] Brown, E.C. & Greenbaum, P.E., Reinstitutionalization After Discharge from Residential Mental
Health Facilities: Competing Risks Survival Analysis.
[20] Kilzer, supra note 10.
[21] Client reports to Bazelon Center staff attorneys.
[22] Mental Health: A Report of the Surgeon General, supra note 1.
[23] Mental Health: A Report of the Surgeon General, supra note 1.
[24] See, e.g., supra note 14 and accompanying text.
[25] National Council on Crime and Delinquency, Focus Newsletter, July 16, 2002 (“[Residential
treatment centers] are usually some distance from the youth’s community, alienating the youth from his or
her known environment and adding communication and travel costs to the families and communities.”)
[26] Myrth Ogilvie, Transitioning From Residential Treatment: Family Involvement & Helpful Supports,
in Focal Point (2001), available at:
http://www.rtc.pdx.edu/FPinHTML/FocalPointSP01/pgFPsp01Transitioning.shtml.
[27] Supra note 25.
[28] Since their inception, RTCs have been under-monitored. As Jane Knitzer noted in Unclaimed
Children, supra note 2 at 46: “States have not emphasized continued monitoring of children’s care once
they are in residential treatment.” Many RTCs are not accredited at all. Further, the RTCs that are
certified are accredited by the Joint Organization on Accreditation of Healthcare Organizations (JCAHO),
an independent, nonprofit organization. But as many have pointed out “JCAHO’s standards are geared
mainly toward monitoring surgical and pharmacological procedures. And so RTCs, which are more like
boarding schools than traditional hospitals, can become accredited under standards that have little to do
with the daily programs and activities practiced in them.” Meza-Wilson, A. & Harrison, C., Safe Choices
for Troubled Teens: Residential treatment centers for troubled teens are plagued by allegations of abuse
and ineffectiveness. But do anguished parents have an alternative?, August 12, 2004, available at:
http://www.askquestions.org/articles/teens/.
[29] Ohio Rights Service Review, supra note 5.
[30] Id. Further, the Bazelon Center has been contacted by federally funded Protection and Advocacy
organizations who never or rarely received MUIs from the RTCs serving children within their
jurisdiction.
[31] Friesen, B.J., Kruzich, J.M., Robinson, A., Jivanjee, P., Pullmann, M. & Bowles, C., Straining the
Ties that Bind: Limits on Parent-Child Contact in Out-Of-Home Care, in Focal Point (2001), available at:
http://www.rtc.pdx.edu/FPinHTML/FocalPointSP01/pgFPsp01Straining.shtml.
[32] See e.g., Scott Higham and Sewell Chan, Poor Care, Abuses Alleged at Riverside, The Washington
Post, July 15, 2003, available at: http://www.washingtonpost.com/ac2/wpdyn?pagename=article&contentId=A56180-2003Jul14&notFound=true; Kilzer, supra note 10;
Associated Press, Death At Residential Treatment Center Ruled a Homicide, May 16, 2002, available at:
http://www.geocities.com/ahobbit.geo/residential_treatment.html; Tim Weiner, Parents Divided Over
Jamaica Disciplinary Academy, The New York Times, June 17, 2003; Ohio Rights Service Review, supra
note 5; Tanya Eiserer, Death of teen at therapy facility investigated: Richardson 17-year-old died being
restrained by staff in Hill Country, Dallas Morning News, October 17, 2002; Jorge Fitz-Gibbon, Leah Rae
and Shawn Cohen, Treatment Often Hampered By Bureaucracy, The Journal News, June 23, 2002,
available at: http://www.nyjournalnews.com/rtc/rtc062302_01.html.
[33] Higham and Chan, supra note 32.
[34] Reports to staff attorneys at the Bazelon Center for Mental Health Law.
[35] Kilzer, supra note 10.
[36] Unclaimed Children, supra note 2, at 46.
[37] Kilzer, supra note 10.
[38] Higham and Chan, supra note 32.
[39] Fitz-Gibbon, Rae and Cohen, supra note 32.
[40] Id.
[41] Higham and Chan, supra note 32.
[42] Associated Press, supra note 32.
[43] Fitz-Gibbon, Rae and Cohen, supra note 32.
[44] Kilzer, supra note 10.
[44] Higham and Chan, supra note 32.
[45] Fitz-Gibbon, Rae and Cohen, supra note 32.
[46] Id.
[47] Mental Health: Report of the Surgeon General, supra note 1.
[48] Id.
[49] Id. The Surgeon General suggests that RTCs are often utilized because of the under-availability of
community-based alternatives.
[50] Bruns, E.J., Serving Youths with Emotional and Behavioral Problems in Maryland: Opportunities for
the Use of the Wraparound Approach, University of Maryland School of Medicine, Department of
Psychiatry, September 17, 2003 (on file at the Bazelon Center).
[51] Id. at 2.
Source: Judge David L. Bazelon Center for Mental Health Law
1101 15th Street, NW, Suite 1212
Washington, DC 20005
Phone: 202-467-5730
Fax: 202-223-0409
Email: webmasteratbazelon.org
Top 10 Residential Treatment Center Deficiencies
January 1, 2008 through May 31, 2009
Standard Rule *
Description
Deficiencies Rank
748.3301(a)
Physical Site-Buildings must be structurally sound,
clean, and in good repair. Paints must be lead-free
88
1
748.507(1)
Employee general responsibilities-Demonstrate
competency, prudent judgment, self-control in
presence of children and when performing assigned
tasks
65
2
748.685(a)(4)
Caregiver responsibility - providing the level of
supervision necessary to ensure each child's safety
and well-being
65
2
748.3391(a)
Bathrooms-Must be maintained in good repair & kept
clean
50
4
748.2151(a)(8)
Medication Record-Must include accurate running
count of each prescribed medication
47
5
748.3301(i)
Physical Site-Equipment and furniture must be safe for
41
children and must be kept clean and in good repair
6
748.3365(a)(3)
Bedding-Must provide each child with a mattress cover
28
or protector or mattress that is waterproof or washable
7
745.625(a)(7)
Background checks submitted-every 24 months after
first submitted
26
8
25
9
Physical Site-Windows & doors must be in good repair
25
& free of broken glass or hazards
9
Mandatory drug testing-all applicants intended to be
745.4151(c)(4)(A) hired are subject to pre-employment testing, must
have results prior to child access
748.3301(c)
* Only includes deficiencies where the administrative review was upheld or waived.
Source: Texas Department of Family and Protective Services (www.dfps.state.tx.us)
Checklist: Gathering
Information from the RTC
Provide them a copy of the order of appointment for their records
Ask for a packet of information on their RTC and how it operates
What are the goals of the RTC?
What is the capacity of the RTC? (how many beds?, are they full?)
What is the staff:child ratio?
What are the educational levels of staff? Of the therapists?
Is staff turnover likely to occur while the child/youth is at their RTC?
How long is the average length of stay for a child/youth placed there?
What are the different Levels of Care (LOC) served by the RTC?
How often does Youth for Tomorrow (YFT) assess the children and/or youth placed
there?
Ask for a copy of the organizational chart
Ask for a copy of the daily schedule
What are the rules regarding who the child can initiate contact with and when? Can
they be given a phone card to make long-distance calls?
What is the best time for CASA to call the child?
What is the best time for CASA to visit the child?
Is there a protocol CASA should follow to set the appointment that indicates who
the contact person is? How much notice is required in scheduling a visit with the
child?
What is the visitation policy for parents, siblings, relatives, past caretaker?
Would the child be given access to a telephone to join their hearing via conference
call?
Ask for a copy or an explanation of the behavioral management system (levels,
privileges)
Ask for a copy of the resident handbook (if there is one)
What items can the child have and specifically NOT have?
How do they view CASA’s role?
What has their previous experience with CASA been like (if they’ve had one)?
How do I get copies of: the treatment plan, therapy notes, daily activity notes or like
records?
Who can I speak to get notified of “staffings” or “treatment team meetings”?
How often is progress on the treatment plan assessed?
Who do you rely on for diagnosis?
Who do I contact if I have concerns?
Do you have a process for requesting/obtaining a second opinion?
How do you determine a child has met the goals and can be returned to a less
restrictive environment?
How will the family/previous caretaker be involved in the treatment?
What is the medication policy? For example, is a child/youth removed from current
meds, re-evaluated and started on a new regime? Or are their medications
continued with a gradual change, if needed?
Who is the psychiatrist the facility uses?
Who is the Director of the RTC?
Can I have the names of everyone on the Interdisciplinary Team that will be
involved in the child’s care?
Can I have a tour?
quick reference to psychotropic medication®
Developed by John Preston, Psy.D., ABPP
To the best of our knowledge recommended doses and side effects listed below are accurate. However, this is meant as a general reference only, and should not serve as a guideline for prescribing
of medications. Please check the manufacturer’s product information sheet or the P.D.R. for any changes in dosage schedule or contraindications. (Brand names are registered trademarks.)
antidepressantS
UsualSelective Action On
Daily DosageNeurotransmitters2
Range
Sedation ACH1
NE
5-HT
DA
NAMES
Generic
Brand
imipramine
desipramine
amitriptyline
nortriptyline
protriptyline
trimipramine
doxepin
clomipramine maprotiline
amoxapine
trazodone
fluoxetine
bupropion-X.L.
sertraline
paroxetine
venlafaxine-X.R.
fluvoxamine
mirtazapine
citalopram
escitalopram
duloxetine
atomoxetine
mao inhibitors
phenelzine
tranylcypromine
selegiline
Tofranil
Norpramin
Elavil
Aventyl, Pamelor
Vivactil
Surmontil3
Sinequan, Adapin3
Anafranil
Ludiomil
Asendin
Desyrel
Prozac4, Sarafem
Wellbutrin-X.L.4
Zoloft
Paxil
Effexor-X.R.4
Luvox
Remeron
Celexa
Lexapro
Cymbalta
Strattera
150-300
150-300
150-300
75-125
15-40
100-300
150-300
150-250
150-225
150-400
150-400
20-80
150-400
50-200
20-50
75-350
50-300
15-45
10-60
5-20
20-80
60-120
Nardil
Parnate
Emsam (patch)
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
30-90 mg
20-60 mg
6-12 mg
mid
low
high
mid
mid
high
high
high
high
mid
mid
low
low
low
low
low
low
mid
low
low
low
low
mid
low
high
mid
mid
mid
mid
high
mid
low
none
none
none
none
low
none
low
mid
none
none
none
low
++
+++++
++
+++
++++
++
++
0
+++++
+++
0
0
++
0
+
++
0
+++
0
0
++++
+++++
+++
0
++++
++
+
++
+++
+++++
0
++
++++
+++++
0
+++++
+++++
+++
+++++
+++
+++++
+++++
++++
0
0
0
0
0
0
0
0
0
0
0
0
0
++
0
0
+
0
0
0
0
0
0
low
low
low
none
none
none
+++
+++
+++
+++
+++
+++
+++
+++
+++
ACH: Anticholinergic Side Effects
NE: Norepinephrine, 5-HT: Serotonin, DA: Dopamine (0 = no effect, + = minimal effect, +++ = moderate effect, +++++ = high effect)
3
Uncertain, but likely effects
4
Available in standard formulation and time release (XR, XL or CR). Prozac available in 90mg time released/weekly formulation
1
2
BIPOLAR DISORDER MEDICATIONS
NAMES
Generic Brand
lithium carbonate
olanzapine/
fluoxetine
carbamazepine
oxcarbazepine
DailySerum1
Dosage Range Level
Eskalith, Lithonate 600-2400 0.6-1.5
Symbyax 6/25-12/50mg4
Tegretol,Equetro 600-1600
Trileptal
1200-2400
2
4-10+
(2)
NAMES
GenericBrand Dosage divalproex
gabapentin
lamotrigine
topiramate
tiagabine
Depakote
Neurontin
Lamictal
Topamax
Gabitril
DailySerum1
Range
Level
750-1500 50-100
300-2400
(2)
50-500
(2)
50-300
(3)
4-12
(3)
Lithium levels are expressed in mEq/l, carbamazepine and valproic acid levels express in mcg/ml.
Serum monitoring may not necessary 3Not yet established 4Available in: 6/25, 6/50, 12/25, and 12/50mg formulations
1
2
anti-obsessional
NAMES
Generic
Brand
Dose Range1
clomipramine
Anafranil
150-300
fluoxetine
Prozac1
20-80
sertraline
Zoloft1
50-200
paroxetine
Paxil1
20-60
fluvoxamine
Luvox1
50-300
citalopram
Celexa1
10-60
escitalopram
Lexapro1
5-30
1often higher doses are required to control obsessive-compulsive
symptoms than the doses generally used to treat depression.
© Copyright 2007, John Preston, Psy.D and P.A. Distributors
mg
mg
mg
mg
mg
mg
mg
psycho-stimulants
NAMES
Generic
Brand
methylphenidate
methylphenidate
methylphenidate
methylphenidate
methylphenidate
dexmethylphenidate
dextroamphetamine
lisdexamphetamine
pemoline
d- and l-amphetamine
modafinil
Note: Adult Doses.
1
2
Daily Dosage1
Ritalin
5-50
Concerta2
18-54
Metadate
5-40
Methylin
10-60
Daytrana (patch)15-30
Focalin
5-40
Dexedrine
5-40
Vyvanse
30-70
Cylert
37.5-112.5
Adderall
5-40
Provigil, Sparlon100-400
Sustained release
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
antipsychotics
NAMES
Generic
Brand Dosage Range1 Sedation Ortho2
EPS3
low potency
chlorpromazine
thioridazine
clozapine
mesoridazine
quetiapine
high potency
molindone
perphenazine
loxapine
trifluoperazine
fluphenazine
thiothixene
haloperidol
pimozide
risperidone
paliperidone
olanzapine
ziprasidone
aripiprazole
Thorazine
Mellaril
Clozaril
Serentil
Seroquel
50-800
150-800
300-900
50-500
150-600
Moban
Trilafon
Loxitane
Stelazine
Prolixin5
Navane
Haldol5 Orap
Risperdal
Invega
Zyprexa
Geodon
Abilify
mg
mg
mg
mg
mg
high
high
high
high
mid
high
high
high
mid
mid
20-225 mg
8-60 mg
50-250 mg
2-40 mg
3-45 mg
10-60 mg
2-40 mg
1-10 mg
4-16 mg
3-12 mg
5-20 mg
60-160 mg
15-30mg
low
mid
low
low
low
low
low
low
low
low
mid
low
low
mid
mid
mid
mid
mid
mid
low
low
mid
mid
low
mid
low
ACH
Effects4
++
+
0
+
+/0
++++
+++++
+++++
+++++
+
+++
++++
+++
++++
+++++
++++
+++++
+++++
+
+
+/0
+/0
+/0 +++
++
++
++
++
++
+
+
+
+
+
++
+
Equivalence5
100
100
50
50
50
mg
mg
mg
mg
mg
10 mg
10 mg
10 mg
5 mg
2 mg
5 mg
2 mg
1-2 mg
1-2 mg
1-2mg
1-2 mg
10 mg
2 mg
Usual daily oral dosage
Orthostatic Hypotension Dizziness and falls
3
Acute: Parkinson’s, dystonias, akathisia. Does not reflect risk for tardive dyskinesia. All neuroleptics may cause tardive dyskinesia, except clozapine.
4
Anticholinergic Side Effects.
5
Dose required to achieve efficacy of 100 mg chlorpromazine.
6
Available in time-release IM format.
1
2
anti-anxiety
NAMESSingle Dose
Generic
Brand
Dosage Range
benzodiazepines
diazepam
Valium
2-10
chlordiazepoxide Librium
10-50
prazepam
Centrax
5-30
clorazepate
Tranxene
3.75-15
clonazepam
Klonopin
0.5-2.0
lorazepam
Ativan
0.5-2.0
alprazolam
Xanax, XR
0.25-2.0
oxazepam
Serax
10-30
other antianxiety agents
buspirone
BuSpar
5-20
gabapentin
Neurontin
200-600
hydroxyzine
Atarax, Vistaril 10-50
propranolol
Inderal
10-80
atenolol
Tenormin
25-100
guanfacine
Tenex
0.5-3
clonidine
Catapres
0.1-0.3
prazosin
Minipress
5-20
Doses required to achieve efficacy of 5 mg of diazepam
1
Over the counter
Name
Daily Dose
St. John’s Wort SAM-e3
Omega-34
600-1800 mg
400-1600 mg
1-9 g
1, 2
Treats depression and anxiety
May cause signifigant drug-drug interactions
3
Treats depression
4
Treats depression and bipolar disorder
1
2
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
mg
Equivalence
5
25
10
10
0.25
1
0.5
15
mg
mg
mg
mg
mg
mg
mg
mg
1
hypnotics
NAMES
Single Dose
Generic
Brand Dosage Range
flurazepam
temazepam
triazolam
estazolam
quazepam
zolpidem
zaleplon
eszopiclone
ramelteon
diphenhydramine
Dalmane
Restoril
Halcion
ProSom
Doral
Ambien
Sonata
Lunesta
Rozerem
Benadryl
common side effects
anticholinergic effects
(block acetylcholine)
• dry mouth
• constipation
• urinary retention
• blurred vision
• memory impairment
• confusional states
extrapyramidal effects
(dopamine blockade in basal ganglia)
• Parkinson-like effects: rigidity, shuffling gait, tremor, flat affect,
lethargy
• Dystonias: spasms in neck and other muscle groups
• Akathisia: intense, uncomfortable sense of inner restlessness
• Tardive dyskinesia: often a persistent movement disorder (lip
smacking, writhing movements, jerky movements)
Note: The above are common side effects. All medications can
produce specific or unique side effects. For a more complete
description, please see references listed below
references and recommended books
Handbook of Clinical
Psychopharmacology For Therapists
(2008) Preston, O’Neal and Talaga
15-30 mg
15-30 mg
0.25-0.5 mg
1.0-2.0 mg
7.5-15 mg
5-10 mg
5-10 mg
1-3 mg
4-16 mg
25-100 mg
Quick Reference • Free Downloads
Website: www.PsyD-fx.com
Clinical Psychopharmacology Made
Ridiculously Simple 5th Edition
(2008) Preston and Johnson
AF
T
Psychotropic Medication Utilization Parameters
for Foster Children
DR
Developed by:
Texas Department of Family and Protective Services
and
The University of Texas at Austin College of Pharmacy
with review and input provided by:
v Federation of Texas Psychiatry
v Texas Pediatric Society
v Texas Academy of Family Physicians
v Texas Medical Association
September 2010
Psychotropic Medication Utilization Parameters
2
Table of Contents
◆◆ Introduction and General Principles....................................................................... 3-7
◆◆ Criteria Indicating Need for Further Review of a Child's Clinical Status......................8
T
◆◆ Members of the Ad Hoc Working Group.....................................................................9
AF
◆◆ References.......................................................................................................... 10-11
◆◆ Medication Charts............................................................................................. 12-18
DR
◆◆ Glossary...................................................................................................................19
September 2010
Psychotropic Medication Utilization Parameters
3
Psychotropic Medication Utilization Parameters
for Foster Children
Introduction and General Principles
to perform such an assessment. It is recognized that in some situations, it may be
in the best interest of the child to prescribe
psychotropic medications before a physical exam can actually be performed. In
these situations, a thorough health history
should be performed to assess for significant medical disorders and past response
to medications, and a physical evaluation
should be performed as soon as possible.
The mental health assessment should be
performed by an appropriately qualified
mental health professional or appropriate
primary care physician with experience in
providing mental health care to children.
The child’s symptoms and functioning
should be assessed across multiple domains,
and the assessment should be developmentally appropriate. It is very important
that information about the child’s history
and current functioning be made available to the treating physician in a timely
manner, either through an adult who is
well-informed about the child or through a
comprehensive medical record. It is critical to meet the individual needs of patients
and their families in a culturally competent
manner. This indicates a need to address
communication issues as well as differences
in perspective on issues such as behavior
and mental functioning. At present there
are no biomarkers to assist with the diagnosis of mental disorders, and imaging (e.g.,
MRI) and other tests (e.g., EEG) are not
generally helpful in making a clinical diagnosis of a mental disorder.
gering the child or others; when there is
marked disturbance of psychophysiological functioning (such as profound sleep
disturbance), or when the child shows
marked anxiety, isolation, or withdrawal.
Given the unusual stress and change in
environmental circumstances associated
with being a foster child, counseling or psychotherapy should generally begin before or
concurrent with prescription of a psychotropic medication. Patient and caregiver
education about the mental disorder, treatment options (non-pharmacological and
pharmacological), treatment expectations,
and potential side effects should occur
before and during the prescription of psychotropic medications.
DR
AF
T
T
he use of psychotropic medications
by children is an issue confronting
parents, other caregivers, and health
care professionals across the United States.
Foster children, in particular, have multiple
needs, including those related to emotional
or psychological stress. Foster children typically have experienced abusive, neglectful,
serial or chaotic care taking environments.
Birth family history is often not available.
These children often present with a fluidity
of different symptoms over time reflective
of past traumatic and reactive attachment
difficulties that may mimic many overlapping psychiatric disorders. Establishment
of rapport is often difficult. These multiple
factors serve to complicate diagnosis. Foster
children may reside in areas of the state
where mental health professionals such as
child psychiatrists are not readily available.
Similarly, caregivers and health providers
may be faced with critical situations that
require immediate decisions about the care
to be delivered. For these and other reasons, a need exists for treatment guidelines
and parameters regarding the appropriate
use of psychotropic medications in foster
children.
Because of the complex issues involved in
the lives of foster children, it is important
that a comprehensive evaluation be performed before beginning treatment for a
mental or behavioral disorder. Except in
the case of an emergency, a child should
receive a thorough health history, psychosocial assessment, mental status exam,
and physical exam before the prescribing
of psychotropic medication. Psychological
testing may be particularly useful in clarifying a diagnosis and informing appropriate treatment. The physical assessment
should be performed by a physician or
another healthcare professional qualified
The role of non-pharmacological interventions should be considered before beginning a psychotropic medication, except
in urgent situations such as suicidal ideation, psychosis, self injurious behavior,
physical aggression that is acutely dangerous to others, or severe impulsivity endan-
September 2010
It is recognized that many psychotropic
medications do not have Food and Drug
Administration (FDA) approved labeling
for use in children. The FDA has a statutory mandate to determine whether pharmaceutical company sponsored research
indicates that a medication is safe and effective for those indications that are listed in
the approved product labeling. The FDA
assures that information in the approved
product labeling is accurate, and limits the
manufacturer’s marketing to the information contained in the approved labeling.
The FDA does not regulate physician and
other health provider practice. In fact,
the FDA has stated that it does “not limit
the manner in which a practitioner may
prescribe an approved drug.” Studies and
expert clinical experience often support
the use of a medication for an “off-label”
use. Physicians should utilize the available
evidence, expert opinion, their own clinical
experience, and exercise their clinical judgment in prescribing what is best for each
individual patient.
Psychotropic Medication Utilization Parameters
Primary care providers play a valuable role
in the care of youth with mental disorders. Not only are they the clinicians most
likely to interact with children who are in
distress due to an emotional or psychiatric disorder, inadequate numbers of child
psychiatrists are available to meet all of the
mental health needs of children. Primary
care clinicians are in an excellent position to
perform screenings of children for potential
mental disorders, and they should be able to
diagnose and treat relatively straightforward
situations such as uncomplicated ADHD,
anxiety, or depression. As always, consideration should be given regarding the need
for referral for counseling, psychotherapy,
or behavioral therapy.
• Except in the case of an emergency,
informed consent should be obtained
from the appropriate party(s) before
beginning psychotropic medication.
Informed consent to treatment with psychotropic medication entails diagnosis,
expected benefits and risks of treatment,
including common side effects, discussion
of laboratory findings, and uncommon
but potentially severe adverse events.
Alternative treatments, the risks associated with no treatment, and the overall
potential benefit to risk ratio of treatment
should be discussed.
• The frequency of clinician follow-up with
the patient should be appropriate for the
severity of the child’s condition and adequate to monitor response to treatment,
including: symptoms, behavior, function,
and potential medication side effects.
• In depressed children and adolescents, the
potential for emergent suicidality should
be carefully evaluated and monitored.
• If the prescribing clinician is not a child
psychiatrist, referral to or consultation
with a child psychiatrist, or a general
psychiatrist with significant experience
in treating children, should occur if the
child’s clinical status has not experienced
meaningful improvement within a timeframe that is appropriate for the child’s
clinical response and the medication regimen being used.
• Before adding additional psychotropic
medications to a regimen, the child
should be assessed for adequate medication adherence, accuracy of the diagnosis,
the occurrence of comorbid disorders
(including substance abuse and general
medical disorders), and the influence of
psychosocial stressors.
AF
Primary care providers vary in their training, clinical experience, and confidence to
address mental disorders in children. Short
courses and intensive skills oriented seminars may be beneficial in assisting primary
clinicians in caring for children with mental
disorders. Active liaisons with child psychiatrists who are available for phone consultation or referral can be beneficial in assisting
primary care clinicians to meet the mental
health needs of children.
• In making a decision regarding whether
to prescribe a psychotropic medication
in a specific child, the clinician should
carefully consider potential side effects,
including those that are uncommon but
potentially severe, and evaluate the overall
benefit to risk ratio of pharmacotherapy.
T
Role of Primary Care
Providers
4
• During the prescription of psychotropic
medication, the presence or absence of
medication side effects should be documented in the child’s medical record at
each visit.
• Appropriate monitoring of indices such
as height, weight, blood pressure, or
other laboratory findings should be documented.
• Monotherapy regimens for a given disorder or specific target symptoms should
usually be tried before polypharmacy
regimens.
DR
General principles regarding
the use of psychotropic medications in children include:
• A DSM-IV psychiatric diagnosis should
be made before the prescribing of psychotropic medications.
• Clearly defined target symptoms and
treatment goals for the use of psychotropic medications should be identified
and documented in the medical record
at the time of or before beginning treatment with a psychotropic medication.
These target symptoms and treatment
goals should be assessed at each clinic visit
with the child and caregiver. Whenever
possible, recognized clinical rating scales
(clinician, patient, or caregiver assessed,
as appropriate) or other measures should
be used to quantify the response of the
child’s target symptoms to treatment and
the progress made toward treatment goals.
• Doses should usually be started low and
titrated carefully as needed.
• Only one medication should be changed
at a time, unless a clinically appropriate
reason to do otherwise is documented in
the medical record. (Note: starting a new
medication and beginning the dose taper
of a current medication is considered one
medication change).
• The use of “prn” or as needed prescriptions is discouraged. If they are used, the
situation indicating need for the administration of a prn medication should be
clearly indicated as well as the maximum
number of prn doses in a day and a week.
The frequency of administration should
be monitored to assure that these do not
become regularly scheduled medications.
September 2010
• If a medication is being used in a child
for a primary target symptom of aggression associated with a DSM-IV nonpsychotic diagnosis (e.g., conduct disorder,
oppositional defiant disorder, intermittent
explosive disorder), and the behavior
disturbance has been in remission for six
months, then serious consideration should
be given to slow tapering and discontinuation of the medication. If the medication is continued in this situation, the
necessity for continued treatment should
be evaluated at a minimum of every six
months.
• The clinician should clearly document
care provided in the child’s medical
record, including history, mental status assessment, physical findings (when
relevant), impressions, adequate laboratory monitoring specific to the drug(s)
prescribed at intervals required specific to
the prescribed drug and potential known
risks, medication response, presence or
absence of side effects, treatment plan,
and intended use of prescribed medications.
Psychotropic Medication Utilization Parameters
choice. Second generation antipsychotics are prone to cause significant weight
gain in many children, but the risk for the
development of weight gain in youth varies significantly among the 2nd generation
agents. In a recent study over approximately 11 weeks, the average weight gain
was olanzapine (8.5kg), quetiapine (6.1
kg), risperidone (5.3 kg), and aripiprazole
(4.4 kg). Olanzapine and quetiapine also
caused significant increases in cholesterol
and triglycerides, and risperidone increased
triglycerides (Correll 2009). First generation antipsychotics are prone to causing
extrapyramidal side effects. In particular,
youth are especially susceptible to developing acute dystonic reactions from 1st
generation antipsychotics. Similarly, 1st
generation antipsychotics pose a higher risk
for the development of tardive dyskinesia in
chronically treated individuals. If antipsychotics are indicated, the clinician should
carefully evaluate the individual needs of
the child, actively engage the family in
decision-making, evaluate overall benefit to
risk ratio, and when indicated, choose the
antipsychotic that the clinician thinks will
be best tolerated by that child.
AF
The use of psychotropic medication in
young children of preschool ages is a practice that is limited by the lack of evidence
available for use of these agents in this age
group. The Preschool Psychopharmacology
Working Group (PPWG) published guidelines summarizing available evidence for
use of psychotropic medications in this age
group (Gleason 2007). The PPWG was
established in response to the clinical needs
of preschoolers being treated with psychopharmacological agents and the absence of
systematic practice guidelines for this age
group, with its central purpose to attempt
to promote an evidence-based, informed,
and clinically sound approach when considering medications in preschool-aged
children.
The working group’s key points and guidelines are similar to the general principles
regarding the use of psychotropic medication in children already detailed in this
paper. However, the working group’s
algorithms put more emphasis on treating
preschool-aged children with nonpsychopharmacological interventions (for up to 12
weeks) before starting psychopharmacological treatment, in an effort to be very cautious in introducing psychopharmacological
interventions to rapidly developing preschoolers. The working group also emphasizes the need to assess parent functioning
and mental health needs, in addition to
training parents in evidence-based behavior
management, since parent behavior and
functioning can have a large impact on
behavior and symptoms in preschool-aged
children.
T
Use of Psychotropic
Medication in Preschool Age
Children
5
Antipsychotic selection
Significant controversy exists regarding the
use of 2nd generation versus 1st generation
antipsychotics. Most of the data supporting no difference in efficacy between these
two groups of antipsychotics comes from
studies conducted in chronically ill adults
with schizophrenia. Most of the controlled
studies of the use of antipsychotics to treat
behavioral disorders in children have been
performed with 2nd generation antipsychotics, with the best evidence for risperidone. The only study comparing a 1st generation antipsychotic versus 2nd generation
antipsychotics in youth was conducted in
individuals with early onset schizophrenia. The 1st generation agent used in this
study was molindone, an infrequently used
antipsychotic that is known to be weight
neutral or cause weight loss in adults. It is
unknown how the results of this study can
be extrapolated to the treatment of children
with externalizing disorders such as conduct
disorder or oppositional defiant disorders –
the most common situations in which antipsychotics are prescribed in children.
DR
The PPWG guidelines emphasize consideration of multiple different factors when
deciding on whether to prescribe psychotropic medications to preschool-aged children.
Such factors include the assessment and
diagnostic methods utilized in evaluating
the child for psychiatric symptoms/illness,
the current state of knowledge regarding the
impact of psychotropic medication use on
childhood neurodevelopmental processes,
the regulatory and ethical contexts of use of
psychotropic medications in small children
(including available safety information and
FDA status), and the existing evidence base
for use of psychotropic medication in preschool aged children.
Therapeutic Controversies
The publication includes specific guidelines and algorithm schematics developed
by the PPWG to help guide treatment
decisions for a number of psychiatric
disorders that may present in preschoolaged children, including Attention-Deficit
Hyperactivity Disorder, Disruptive
Behavioral Disorders, Major Depressive
Disorder, Bipolar Disorder, Anxiety
Disorders, Post-Traumatic Stress Disorder,
Obsessive-Compulsive Disorder, Pervasive
Developmental Disorders, and Primary
Sleep Disorders.
Antipsychotics vary with regard to their
side effect profiles, and side effects are the
primary basis for individual medication
September 2010
Depression, Suicidality, and Depression
In October 2003, the FDA released a public
health advisory alerting health care professionals to reports of suicidality (suicidal ideation and suicide attempts) in clinical trials
of antidepressants in pediatric populations.
These reports provided the impetus for a
FDA meta-analytic review of short-term
clinical trials of antidepressants in children
and adolescents. These analyses involved
review, assessment, and reclassification of
over 400 case descriptions. This review ultimately resulted in findings of an increased
risk of suicidality during the first few weeks
of antidepressant treatment. The FDA
responded by issuing a black box warning
in October 2004. The black box warning
describes an increased risk of suicidality
(suicidal behavior and ideation) for ALL
antidepressants used in individuals under
the age of 18. The incidence of suicidal
ideations and behaviors in these pooled
analyses was about 4% for those youth
receiving antidepressants compared with
Psychotropic Medication Utilization Parameters
Stimulants and cardiovascular side effects
Both stimulants and atomoxetine cause
small but statistically significant increases in
blood pressure and pulse rate. However, it
is unclear whether these changes are clinically significant. Although case reports of
sudden death in children taking stimulants
have been reported, a causal link has not
been proven (Vitello 2008). However, a
recent case control study suggests that there
may be an association (Gould 2009). It is
thought that underlying cardiac disorders
such as serious structural abnormalities,
cardiomyopathies, serious heart rhythm
disturbances, or other serious cardiac problems may place children at increased risk of
sudden death when stimulants are administered (FDA approved product labeling for
Adderall and Concerta, 2008; Perrin 2008).
The clinician should conduct a careful history of the child and the family regarding
potential heart problems. A thorough physical exam should also be conducted. If the
history and physical provide suspicion of a
cardiac problem, then an electrocardiogram
should be considered before beginning a
stimulant. If the child has a known history
of a cardiac problem, then a cardiology consult should be considered before beginning
a stimulant (Perrin 2008).
effects reported during clinical trials, as well
as those discovered during post-marketing
evaluation. Many tertiary drug information
resources also report information regarding
common adverse effects and precautions for
use with psychotropic medications.
At times, post-marketing evaluation may
detect critical adverse effects associated
with significant morbidity and mortality. The Food and Drug Administration
(FDA) may require manufacturers to revise
product labeling to indicate these critical
adverse effects. If found to be particularly
significant, these effects are demarcated by
a black box outlining the information at the
very beginning of the product labeling, and
have, in turn, been named black box warnings. Black box warnings are the strongest
warning required by the FDA. It is important for clinicians to be familiar with all
medication adverse effects, including black
box warnings, in order to appropriately
monitor patients and minimize the risk of
their occurrence.
DR
AF
The mortality risk of depression is from suicide. Other major suicide risk factors that
should be assessed include: substance abuse,
conduct disorder, life stressors (such as legal
or disciplinary/school problems), interpersonal losses, family and peer discord,
abuse, lack of support, poor interpersonal
problem-solving ability, the tendency to
respond with hostility or overt aggression
to frustration or stress, hopelessness and
cognitive distortions. All youth with depression should be monitored carefully for the
potential presence of suicidal thoughts or
behaviors. This should occur at the time
of initial clinical assessment and upon each
visit follow-up until depression is no longer
present. Assessment of suicidality should
include asking questions about ideation and
frequency, plans, intention, and potential
dangerousness. More frequent visits, combined with follow-up calls as necessary,
should be considered along with appropriate review of safety plans. It is noteworthy
that in one study, the concomitant use of
cognitive behavioral therapy was shown to
decrease the incidence of suicidality associated with SSRI use.
vacations, this has been suggested as one
mechanism to minimize potential effects
on growth. It is questionable whether the
use of stimulants has any effect on ultimate
adult height (Vitello 2008; Swanson 2008).
T
2% on placebo. It is important to note that
no completed suicides were reported in any
of these trials.
6
Stimulants and growth
Parents and caregivers are often concerned
about the possibility that stimulants may
adversely affect growth. This is largely
related to the fact that, at least short term,
stimulants decrease appetite. Although
data from different studies are mixed,
results from the Multimodal Treatment of
ADHD (MTA) study, indicate that weight
loss occurred during the first 3-4 months
of treatment, but this was followed be a
resumption of weight increase. The rate of
growth in height decreased by about 1-3
cm/year over the first 1-3 years of medication treatment. However, it should be
noted that these decreases in height were
only seen in the youth who were adherent
with their stimulant medications. Although
both advantages and disadvantages are
associated with medication holidays or
Distinguishing between Levels
of Warnings Associated with
Medication Adverse Effects
Psychotropic medications have the potential
for adverse effects, some that are treatmentlimiting. Some adverse effects are detected
prior to marketing, and are included in
product labeling provided by the manufacturers. When looking at product labeling,
these adverse effects will be listed in the
“Warnings and Precautions” section. As
well, the “Adverse Reactions” section of the
product labeling will outline those adverse
September 2010
The FDA has in recent years taken additional measures to try and help patients
avoid serious adverse events. New guides
called Medication Guides have been developed, and are specific to particular drugs
and drug classes. Medication Guides advise
patients and caregivers regarding possible adverse effects associated with classes
of medications, and include precautions
that they or healthcare providers may take
while taking/prescribing certain classes of
medications. FDA requires that Medication
Guides be issued with certain prescribed
drugs and biological products when the
Agency determines that certain information is necessary to prevent serious adverse
effects, that patient decision-making should
be informed by information about a known
serious side effect with a product, or when
patient adherence to directions for the use
of a product are essential to its effectiveness.
During the drug distribution process, if a
Medication Guide has been developed for a
certain class of medications, then one must
be provided with every new prescription
and refill of that medication.
Psychotropic Medication Utilization Parameters
Copies of the Medication Guides for psychotropic medications can be accessed on
the FDA website at:
http://www.fda.gov/Drugs/DrugSafety/
ucm085729.htm.
Usual Recommended Doses
of Common Psychotropic
Medications
These are intended to serve as a guide for
clinicians. The tables are not intended to
serve as comprehensive drug information
references or a substitute for sound clinical
judgment in the care of individual patients,
and individual patient circumstances may
dictate the need for the use of higher doses
in specific patients. In these cases, careful documentation of the rationale for the
higher dose should occur, and careful moni-
toring and documentation of response to
treatment should be observed.
Not all medications prescribed by clinicians
for psychiatric diagnoses in children and
adolescents are included below. However,
in general, medications not listed do not
have adequate efficacy and safety information available to support a usual maximum
dose recommendation.
See Medication Charts beginning on page
12.
DR
AF
T
The attached medication charts are intended to reflect usual doses and brief medication information of commonly used psy-
chotropic medications. The preferred drug
list of medications potentially prescribed for
foster children is the same as for all other
Medicaid recipients.
7
September 2010
Psychotropic Medication Utilization Parameters
8
Criteria Indicating Need for Further Review
of a Child’s Clinical Status
T
he following situations indicate a need for further review of a patient’s case. These parameters do not necessarily indicate that
treatment is inappropriate, but they do indicate a need for further review.
For a child being prescribed a psychotropic medication, any of the following suggests the need for additional review of a patient’s
clinical status:
1. Absence of a thorough assessment of DSM-IV diagnosis in the child’s medical record
2. Five (5) or more psychotropic medications prescribed concomitantly (side effect medications are not included in this count)
3. Prescribing of:
T
(a) Two (2) or more concomitant antidepressants (if an additional one is used, may be reviewed but will be allowed if
reasonable for the indications.
(b) Two (2) or more concomitant antipsychotic medications
(c) Two (2) or more concomitant stimulant medications1
(d) Three (3) or more concomitant mood stabilizer medications
AF
NOTE: For the purpose of this document, polypharmacy is defined as the use of two or more medications for the same
indication (i.e., specific mental disorder).
1 The prescription of a long-acting stimulant and an immediate release stimulant of the same chemical entity (e.g.,
methylphenidate) does not constitute concomitant prescribing.
2 When
DR
switching psychotropics, medication overlap and cross-titration may be utilized before discontinuing the first
medication
4. The prescribed psychotropic medication is not consistent with appropriate care for the patient’s diagnosed mental disorder or
with documented target symptoms usually associated with a therapeutic response to the medication prescribed.
5. Psychotropic polypharmacy for a given mental disorder is prescribed before utilizing psychotropic monotherapy.
6. The psychotropic medication dose exceeds usual recommended doses.
7. Psychotropic medications are prescribed for children of very young age, including children receiving the following medications
with an age of:
s Antidepressants:
s Antipsychotics:
s Psychostimulants:
Less than four (4) years of age
Less than four (4) years of age
Less than three (3) years of age
8. Prescribing by a primary care provider who has not documented previous specialty training for a diagnosis other than the following (unless recommended by a psychiatrist consultant):
s
s
s
Attention Deficit Hyperactive Disorder (ADHD)
Uncomplicated anxiety disorders
Uncomplicated depression
September 2010
Psychotropic Medication Utilization Parameters
9
Members of the Ad Hoc Working Group
on Psychotropic Medication Guidelines
for Foster Children
M. Lynn Crismon, Pharm.D., Dean, Doluisio Chair, Behrens Inc. Centennial Professor, College of Pharmacy, University of Texas at
Austin, Austin, TX
James A. Rogers, MD: Medical Director, Texas Department of Family and Protective Services, Austin, TX.
T
Peter Jensen, M.D.: President & CEO The REACH Institute Resource for Advancing Children’s Health. New York City, NY.
Lynn Lasky Clark: President & CEO, Mental Health America of Texas, Austin, TX.
Charles Fischer, MD, Chief Psychiatrist, Child and Adolescent Unit, Austin State Hospital, Austin, TX.
AF
Carroll W. Hughes, PhD, ABPP, Professor of Psychiatry, UT Southwestern Medical Center, Dallas ,TX.
Mark Janes, MD: Medical Director, Burke Center, Lufkin, TX.
James C. Martin, MD, VP for Medical Affairs, Christus Santa Rosa Health Center, San Antonio, TX.
Octavio N. Martinez, Jr., MD., Executive Director Hogg Foundation for Mental Health, University of Texas at Austin, Austin, TX.
Nina Jo Muse, M.D., Child Psychiatrist, Texas Department of State Health Service, and private consultation practice, Austin, TX
Sylvia Muzquiz-Drummond, M.D., Medical Director MHMRA of Harris County, Houston, TX.
DR
Steven Pliszka, M.D., Professor, Vice Chair, and Chief of the Child Psychiatry Division, Department of Psychiatry, University of Texas
Health Science Center at San Antonio. San Antonio, TX
Manuel Schydlower, MD, Associate Academic Dean for Admission Texas Tech University Health Sciences Center Paul L. Foster School
of Medicine at El Paso, El Paso, TX
William C. Streusand, MD, Medical Director, Texas Child Study Center, Seton Family of Hospitals, Austin, TX.
September 2010
Psychotropic Medication Utilization Parameters
10
References
1. 21 CFR Part 201. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs: Revision of “Pediatric
Use” Subsection in the Labeling; Final Rule, Federal Register: December 13, 1994.
2. Advisory Committee on Psychotropic Medications. The use of psychotropic medications for children and youth in the Texas foster care
system. Texas Department of Family and Protective Services, September 1, 2004.
3. American Academy of Pediatrics. Clinical practice guideline: Treatment of the school age child with attention deficit/hyperactivity disorder. Pediatrics 2001;108:1033-44.
4. Blair BS, Scahill L, State M, Martin A. Electro-cardiographic changes in children and adolescents treated with Ziprasidone: A Propective
Study. J Am Acad Child Adolesc Psychiatry 2005; 44:73-79
T
5. Children and Adolescents’ Psychoactive Medication Workgroup. Psychoactive medication for children and adolescents: Orientation for
Parents, Guardians, and Others. Massachusetts Department of Mental Health, Boston, July 2007. http://www.mass.gov/dmh/publications/PsychoactiveBooklet.pdf (accessed May 8, 2009)
6. Crismon ML, Argo T. The Use of Psychotropic Medication for Children in Foster Care. Child Welfare 2009;88:71-100.
AF
7. Correll CU, Manu P, Olshanskiy V, et al; Cardiometabolic risk of second-generation antipsychotic medications during first-time use in
children and adolescents; JAMA 2009; 302(16):1765-73.
8. Dopheide JA. Recognizing and treating depression in children and adolescents. Am J Health-Syst Pharm 2006;63:233-43.
9. Eden J, Wheatley B, McNeil B, Sax, H. Knowing what works in health care: A roadmap for the nation. Washington, DC: National
Academies Press, 2008; 288 pp.
10. Emslie GJ, Hughes CW, Crismon ML, Lopez M, Pliszka S, Toprac MG, Boemer C. A feasibility study of the childhood depression
medication algorithm: the Texas Children’s Medication Algorithm Project (CMAP). J Am Acad Child Adolesc Psychiatry 2004;43:51927.
DR
11. Findling RL, Reed MD, O’Riordan MA, Demeter CA, Stansbery RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of
quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 2006;45:792-800.
12. Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: contexts and guidelines. J Am
Acad Child Adolesc Psychiatry 2007;46:1532-1572.
13. Greenhill LL, AACAP Work Group on Quality Issues. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002; 41(supplement):26S-49S.
14. Gould MS, Walsh BT, Munfakh JL, et al. Sudden Death and Use of Stimulant Medications in Youths. Am J Psychiatry. 2009. 166: 9921001
15. Hughes CW, Emslie GJ, Crismon ML, et al. The Texas childhood medication algorithm project: revision of the algorithm for medication
treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 2007; 46(6):667-686.
16. Jensen PS, Builelaar J, Pandina GJ, Binder C, Haas M. Management of psychiatric disorders in children and adolescents with atypical
antipsychotics. Eur Child Adolesc Psychiatry 2007:16:104-120.
17. Jensen PS and the T-MAY Steering Committee. Treatment of Maladaptive Behavior in Youth (T-MAY). Center for Education and
Research on Mental Health Therapeutics (CERT), Rutgers University, New Brunswick, NJ, 2010; 39 pp.
18. Kowatch RA, DelBello MP. The use of mood stabilizers and atypical antipsychotics in children and adolescents with bipolar disorders.
CNS Spectrum 2003;8:273-80.
19. Kutcher SP. Practical child & adolescent psychopharmacology. Cambridge University Press, Cambridge, UK, 2002; 457 pp.
20. Martin A, Scahill L, Charney DS, Leckman JF (eds). Pediatric Psychopharmacology: Principles and Practice. Oxford University Press,
New York, NY, 2003.
September 2010
Psychotropic Medication Utilization Parameters
11
References (continued)
21. Pappadopulos E, MacIntyre JC, Crismon ML, Findling RL, Malone RP, Derivan A, Schooler N, Sikich L, Greenhill L, Schur SB, Felton
C, Kanzler H, Rube D, Sverd J, Finnerty M, Ketner S, Siennick SE, Jensen PS. Treatment recommendations for the use of antipsychotics for aggressive Youth (TRAAY): Part II. J Am Acad Child Adolesc Psychiatry 2003;42:145-61.
22. Patel NC, Crismon ML, Hoagwood K, Jensen PS. Unanswered questions regarding antipsychotic use in aggressive children and adolescents. Jour Child & Adolesc Psychopharm 2005;15:270-284.
23. Pavuluri MN, Henry DB, Devineni B, Carbray JA, Naylor MW, Janicak PG. A pharmacotherapy algorithm for stabilization and maintenance of pediatric bipolar disorder. J Am Acad Child Adolesc Psychiatry 2004;43:859-67.
24. Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for Attention Deficit/Hyperactivity
Disorder. Pediatrics 2008;122:451-453.
T
25. Pliszka SR. Non-stimulant treatment of attention-deficit hyperactivity disorder. CNS Spectrums 2003;8:253-58.
26. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PT, McCracken JT, Swanson JM, Lopez M, and the Texas
Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit/Hyperactivity Disorder. The Texas Children’s
Medication Algorithm Project: A revision of the algorithm for the pharmacotherapy of childhood Attention Deficit/Hyperactivity
Disorder. J Am Acad Child Adolesc Psychiatry 2006;45:642-57.
AF
27. Pliszka SR, Lopez M, Crismon ML, Toprac M, Hughes CW, Emslie GJ, Boemer C. A feasibility study of the Children’s Medication
Algorithm Project (CMAP) algorithm for the treatment of ADHD. J Am Acad Child Adolesc Psychiatry 2003;42:279-87.
28. Prescribing psychoactive medications for children and adolescents: Policy Statement, American Academy of Child and Adolescent
Psychiatry, Revised and approved by the Council, September 20, 2001,
http://www.aacap.org/cs/root/policy_statements/prescribing_psychoactive_medication_for_children_and_adolescents
29. Psychiatric care of children in the foster care system: Policy Statement, American Academy of Child and Adolescent Psychiatry, Revised
and approved by the Council, September 20, 2001,
http://www.aacap.org/cs/root/policy_statements/psychiatric_care_of_children_in_the_foster_care_system
DR
30. Rush AJ, First MB, Blacker. Handbook of Psychiatric Measures; 2nd ed. Washington, DC. American Psychiatric Pub. 2008.
31. Scahill L, Oesterheld, JR. Martin A. Pediatric psychopharmacology II. General principles, specific drug treatments, and clinical practice.
In: Lewis M (ed.). Child and adolescent psychiatry: A comprehensive textbook. Lippincott Williams & Wilkins, Philadelphia, 2007:
754-788.
32. Schur SB, Sikich L, Findling RL; Malone RP, Crismon ML, Derivan, A, MacIntyre II JC, Pappadopulos E, Greenhill L, Schooler
N, Van Orden K, Jensen PS. Treatments for aggression in children and adolescents: a review. J Am Acad Child Adolesc Psychiatry
2003;42:132-44.
33. Sikich L, Frazier JA, McCelellan J, et al. Double-Blind Comparison of First- and Second-Generation Antipsychotics in Early-Onset
Schizophrenia and Schizoaffective Disorder: Findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS)
Study. Am J Psychiatry. 2008;165(11): 1420-31.
34. Swanson J, Arnold LE, Kraemer H. Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the
Multimodal Treatment Study of Children With ADHD (MTA): Part I: Executive Summary. J Atten Disord. 2008.12: 4-14.
35. Vitiello B. Understanding the Risk of Using Medications for Attention Deficit Hyperactivity Disorder with Respect to Physical Growth
and Cardiovascular Function. Child and adolescent psychiatric clinics of North America. 2008. 17(2):459-474.
36. Wagner KD, Pliszka SR. Treatment of child and adolescent disorders. In: Schaztzberg AF, Nemeroff CB (eds). Textbook of psychopharmacology, 4th. Ed. American Psychiatric Publishing, Washington, DC, 2009: 1309-1371.
Recommendations for primary care providers on when to seek referral or consultation with a child psychiatrist can be found at
http://www.aacap.org/cs/root/physicians_and_allied_professionals/when_to_seek_referral_or_consultation_with_a_child_and_adolescent_psychiatrist
September 2010
Psychotropic Medication Utilization Parameters
12
Stimulants
Drug
Initial
Dosage
Literature
Based
Maximum
Dosage
FDA Approved
Maximum Dosage
for Children and
Adolescents
Amphetamine Mixed Salts
Generic available
5 mg/day
40 mg/day
(30 mg/day-XR)
40 mg/day
Adderall®
Adderall®XR **
Methylphenidate
Generic available
Ritalin®
Ritalin®SR
Ritalin®LA
Metadate®
Metadate®CD
40 mg/day
Not recommended in
children younger than
6 years
IR: Once or twice daily
Spansule: Once daily
30mg/day
70mg/day
70mg/day
Not studied in children
younger than 6 years
Once daily
Abuse potential
Ritalin IR:
10 mg/day
Not recommended for
children younger than
6 years
Ritalin SR:
5 mg/day
Ritalin LA:
20 mg/day
Metadate:
10mg/day
Methylin:
10mg/day
60 mg/day
(30mg/dayDaytrana TD)
(90mg/dayConcerta)
Over 6 years: Ritalin,
Metadate, and Methylin:
60 mg/day
Concerta:
Children:
54 mg/day
Adolescents:
72 mg/day
Ritalin IR: One to three
times daily
Sudden death and
serious cardiovascular
events
Ritalin SR: Once daily
Metadate: Twice daily
• Sudden death in those
with pre-existing structural
cardiac abnormalities or
other serious heart
problems
• Hypertension
• Psychiatric adverse event
• Long-term growth
suppression
Metadate CD: Once daily
Methylin: Twice daily
DR
Methylin®
SR: Once daily
AF
Lisdexamfetamine
Vyvanse®
Not recommended in
children younger than
3 years
40 mg/day
Dexedrine Spansule®
Warnings and Precautions
IR: Once or twice daily
5 mg/day
Dexedrine®
Black Box Warning *
T
Dextroamphetamine
Generic available
(30 mg/day-XR)
Schedule
Methylin®ER
Concerta®
Daytrana® TD
Dexmethylphenidate
Concerta:
18mg/day
Daytrana:
30 mg/day
(largest patch)
DaytranaTD:
10 mg/day
5 mg/day
20 mg/day
Methylin ER: Once daily
Concerta: Once daily
Daytrana TD: Once daily
Focalin 20 mg/day
IR: Twice daily
Focalin®
Focalin XR 30 mg/day
XR: Once daily
Focalin® XR
Not recommended for
children younger than
6 years
* See the FDA approved product labeling for each medication for the full black box warnings.
** IR, immediate-release; SR, sustained-release formulation; CD, combined immediate release and extended release;
ER and XR, extended-release; TD, transdermal.
September 2010
Psychotropic Medication Utilization Parameters
13
Other ADHD Treatments
Drug
Initial Dosage
Literature
Based
Maximum
Dosage
FDA Approved Maximum Dosage for
Children and Adolescents
Atomoxetine
Children:
0.5 mg/kg/day
Children:
1.4 mg/kg/day
Children: 1.4 mg/kg
Adolescents:
40 mg/day
Adolescents:
80-100 mg/day
0.05 mg/day
0.4 mg/day
0.5 mg/day
4 mg/day
Bupropion
Generic available
Children:
75 mg/day
Wellbutrin®
Wellbutrin®SR
Wellbutrin®XL
Adolescents:
100-150 mg/
day
The lesser
of:3-6 mg/kg/
day OR
400 mg/day
(SR)
Clonidine
Generic available
Tenex®
Intuniv®
Maximum dosage should not exceed
1.4 mg/kg/day or 100 mg/day,
whichever is less
Not approved for children and
adolescents
Sustained release (brand name
Intuniv™) approved for treatment of
ADHD in children and adolescents up
to 4mg/day
450 mg/day
(XL)
Not approved for children and
adolescents
Sustained or extended release
formulation is recommended.
Sustained release tablets may be
halved prior to administration; however,
partial tablets will degrade upon prolonged atmospheric exposure.
DR
Extended release tablets cannot be
split prior to administration.
Imipramine
Generic available
Tofranil®
1 mg/kg/day
Nortriptyline
Generic available
Aventyl®
Pamelor®
Nortrilen®
Once
or twice
daily
None
Black Box Warning
Suicidal thinking in
children and
adolescents being
treated for ADHD
Once to
four times
daily
0.5 mg/kg/day
4 mg/kg/day
OR
300 mg/day
(Adolescents)
2.5 mg/kg/day
OR
150 mg/day
(Adolescents)
Warnings and Precautions
• Liver injury
• Serious cardiovascular
events, including sudden
death, particularly in those
with pre-existing structural
cardiac abnormalities or
other serious heart
problems
• Increases in blood pressure and heart rate
• Psychiatric adverse events
Once to
four times
daily
None
None
Approved for treatment of enuresis in
children 6 years and older
2.5 mg/kg/day
Not approved for children and
adolescents
IR: Once
to three
times
daily
None
SR: Once
to twice
daily
XL: Once
daily
Twice
daily
• Pulse
• ECG
Twice
daily
• Pulse
• ECG
September 2010
• Sedation
• Hypotension
None
AF
Catapres®
Guanfacine
Generic available
Adolescents: 100 mg/day
Baseline/
Monitoring
T
Strattera®
Schedule
Increased risk of
suicidal thinking and
behavior (suicidality)
in short-term studies
in children and adolescents with major
depressive disorder
(MDD) and other psychiatric disorders
• Use in combination with
MAOIs
• Suicidal ideation
• Activation of
mania/hypomania
• Discontinuation syndrome
• Increased risk of bleeding
Psychotropic Medication Utilization Parameters
14
Antidepressants, SSRIs
Drug
Starting Dose
Initial Target
Dose
Literature
Based
Maximum
Dosage
FDA Approved
Maximum Dosage
for Children and
Adolescents
Citalopram
Generic available
Children:
10-20 mg/day
Children:
20 mg/day
Children:
40mg/day
Celexa®
Adolescents:
10-20mg/day
Adolescents:
20 mg/day
Adolescents:
40mg/day
Escitalopram
Lexapro®
Children:
5-10 mg/day
Children:
10 mg/day
Children:
20mg/day
Not approved for
children
Adolescents:
5-10 mg/day
Adolescents:
10 mg/day
Adolescents:
20mg/day
Adolescents
20 mg/day
Fluoxetine
Generic available
Children:
mg (or less)/day
Children:
10-20 mg/day
Children:
30-60mg/day
Prozac®
Adolescents:
10-20 mg/day
Adolescents:
10-20 mg/day
Adolescents:
60mg/day
Approved for
pediatric patients
8 to 18 years
Schedule
Patient
Monitoring
Parameters
Black Box Warning
Warnings and
Precautions
T
Not approved for
children and
adolescents
1) Pregnancy
test –
as clinically
indicated
Increased the risk of
suicidal thinking and
behavior (suicidality)
in short-term studies
in children and adolescents with major
depressive disorder
(MDD) and other psychiatric disorders
AF
For MDD
20 mg/day
Once
daily
For OCD
60 mg/day
Paroxetine
Generic available
Children: Not
Recommended
Children: Not
Recommended
Children: Not
Recommended
Paxil®
Paxil CR®
Adolescents:
10-20mg/day
Adolescents:
10-20 mg/day
Adolescents:
40 mg/day
Not approved for
children and
adolescents
2) Monitor for
emergence
of suicidal
ideation or
behavior
• Use in combination with
MAOIs
• Suicidal ideation
• Activation of mania/
hypomania
• Discontinuation
syndrome
• Increased risk of
bleeding
or
37.5 mg/day
for Paxil CR®
Children: 25mg/
day
Children:
25-75 mg/day
Children:
200 mg/day
Zoloft®
Adolescents:
25-50 mg/day
Adolescents:
50-150 mg/day
Adolescents:
200 mg/day
Approved for
treatment of OCD
in children and
adolescents
200 mg/day
DR
Sertraline
Generic available
From Black Box Warning on package inserts: Patients of all ages who are started on antidepressant therapy should be monitored appropriately
and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for
close observation and communication with the prescriber. Both patients and families should be encouraged to contact the clinician if depression
worsens, the patient demonstrates suicidal behavior or verbalizations, or if medication side effects occur. The appropriate utilization of non-physician clinical personnel who are knowledgeable of the patient population can aid in increasing the frequency of contact between the clinic and the
patient/parent.
September 2010
Psychotropic Medication Utilization Parameters
15
Antidepressants, SNRIs
Duloxetine
Cymbalta®
Literature
Based
Maximum
Dosage
Children:
Insufficient
Evidence
Children:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
Children:
Insufficient
Evidence
Children:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
FDA Approved
Maximum
Dosage for
Children and
Adolescents
Schedule
Patient
Monitoring
Parameters
Black Box Warning
Warnings and Precautions
1) Pregnancy test – as clinically indicated.
Not approved
for children and
adolescents
Insufficient
Evidence
2) Blood pressure during
dosage titration and as clinically necessary
3) Monitor for emergence of
suicidal ideation or behavior
T
Venlafaxine
Extended
Release
Effexor XR®
Starting
Dose
1) Pregnancy test – as clinically indicated
Not approved
for children and
adolescents
Insufficient
Evidence
2) Blood pressure prior to
initiating treatment, during
dosage titration, and as clinically indicated
Increased the risk of
suicidal thinking and
behavior (suicidality)
in short-term studies in
children and adolescents
with major depressive
disorder (MDD) and other
psychiatric disorders
• Use in combination with MAOIs
• Suicidal ideation
• Activation of mania/hypomania
• Discontinuation syndrome
• Increased risk of bleeding
AF
Drug
3) Hepatic function testing
– baseline and as clinically
indicated
4) Monitor for emergence of
suicidal ideation or behavior
Children:
Insufficient
Evidence
Children:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
Adolescents:
Insufficient
Evidence
1) Pregnancy test – as clinically indicated
Not approved
for children and
adolescents
Insufficient
Evidence
2) Blood pressure prior to
initiating treatment, during
dosage titration, and as clinically indicated
DR
Desevenlafaxine
Pristiq®
3) Hepatic function testing
– baseline and as clinically
indicated
4) Monitor for emergence of
suicidal ideation or behavior
From Black Box Warning on package inserts: Patients of all ages who are started on antidepressant therapy should be monitored appropriately
and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for
close observation and communication with the prescriber. Both patients and families should be encouraged to contact the clinician if depression
worsens, the patient demonstrates suicidal behavior or verbalizations, or if medication side effects occur. The appropriate utilization of non-physician clinical personnel who are knowledgeable of the patient population can aid in increasing the frequency of contact between the clinic and the
patient/parent.
September 2010
Psychotropic Medication Utilization Parameters
16
Antipsychotics: Second Generation (Atypical) †
Drug
Aripiprazole
Abilify®
Initial Dosage
Literature Based
Maximum Dosage
Children:
2.5 mg/day
Children:
15mg/day
Adolescents:
5 mg/day
Adolescents:
30mg/day
FDA Approved Maximum
Dosage for Children and
Adolescents
Approved for Bipolar Mania
or Mixed Episodes in
pediatric patients (10 to 17
years) and Schizophrenia in
adolescents (13-17 years)
30mg/day
Schedule
Once daily
Children:
300 mg/day
Adolescents:
25 mg/day
Adolescents:
600 mg/day
Children:
2.5 mg/day
Children:
12.5 mg/day
Adolescents: 2.5-5
mg/day
Adolescents:
30 mg/day
Risperidone
Generic available
Children:
0.25 mg/day
Children:
1.5-2 mg/day
Risperdal®
Adolescents:
0.5 mg/day
Adolescents:
2-6 mg/day
Seroquel®
Approved Bipolar Mania (1017 years) and
for Schizophrenia in
adolescents (13-17 years)
600mg/day
Once to
twice daily
Not approved for children
Zyprexa®
Approved for Bipolar Mania
or Mixed Episodes and
Schizophrenia in adolescents
(13-17 years)
20mg/day
Once to
twice daily
Not approved for children
Approved for Bipolar Mania
or Mixed Episodes in children
and adolescents (10-17
years) and Schizophrenia in
adolescents (13-17 years)
6 mg/day
Once to
twice daily
Irritability associated with
Autistic Disorder (5-16 years)
3 mg/day
Children:
6.25-12.5 mg/day
Children:
150-300 mg/day
Clozaril®
Fazaclo®
Adolescents: 6.2525 mg/day
Adolescents:
200-600 mg/day
Not approved for children
and adolescents
Once daily
DR
Clozapine
Generic available
Asenapine
(sublingual)
Insufficient
Evidence
Insufficient Evidence
Not approved for children
and adolescents
Insufficient
Evidence
Insufficient
Evidence
Insufficient Evidence
Not approved for children
and adolescents
Insufficient
Evidence
Insufficient
Evidence
Insufficient Evidence
Not approved for children
and adolescents
Insufficient
Evidence
Children:
10 mg/day
Children:
Insufficient Evidence
Not approved for children
and adolescents
Adolescents:
20 mg/day
Adolescents:
160 mg/day
Saphris®
Iloperidone
Fanapt®
Paliperidone
Invega®
Ziprasidone
Geodon®
4) Fasting plasma glucose level or
hemoglobin A1c – before initiating a new
antipsychotic, then yearly.
If a patient has significant risk factors
for diabetes and for those that are
gaining weight – before initiating a new
antipsychotic, 4 months after starting an
antipsychotic, and then yearly.
5) Lipid screening [total cholesterol, lowand high-density lipoprotein (LDL and
HDL) cholesterol, and triglycerides] –
Every 2 years or more often if lipid levels
are in the normal range, every 6 months
if the LDL level is > 130 mg/dl
Twice daily
(Better
absorbed
when taken
with food)
6) Sexual function inquiry – inquire
yearly for evidence of galactorrhea/
gynecomastia, menstrual disturbance,
libido disturbance or erectile/ejaculatory
disturbances in males.
If a patient is receiving an antipsychotic
known to be associated with Prolactin
elevation, then at each visit (quarterly
for inpatients) for the first 12 months
after starting an antipsychotic or until
the medication dose is stable and then
yearly
7) EPS Evaluation (examination for rigidity, tremor, akathisia) – before initiation
of any antipsychotic medication, then
weekly for the first 2 weeks after initiating treatment with a new antipsychotic
or until the dose has been stabilized
and weekly for 2 weeks after a dose
increase.
8) Tardive Dyskinesia evaluation – every
12 months. For high risk patients (including the elderly), every 6 months..
9) Vision questionnaire – ask whether
the patient has experienced a change in
vision and should specifically ask about
distance vision and blurry vision – yearly
10) Ocular evaluations – every 2 years
in youth ‡
11) EKG – Baseline and as clinically indicated (Asenapine, Iloperidone,
Paliperidone and Ziprasidone) §
Warnings and
Precautions
Not approved for
depression in under age
18. Increased the risk
of suicidal thinking and
behavior in short-term
studies in children and
adolescents with major
depressive disorder
and other psychiatric
disorders
None related to youth
AF
Olanzapine
3) Weight and BMI measurement –
when a new antipsychotic is initiated,
at every visit (monthly for inpatients) for
6 months after the new antipsychotic is
initiated, and quarterly when the antipsychotic does is stable.
Black
Box
Warning
T
Children:
12.5 mg/day
1) CBC as indicated by guidelines
approved by the FDA in the product
labeling.
2) Pregnancy test – as clinically indicated
Irritability associated with
autistic disorder (6-17 years)
15mg/day
Quetiapine
Patient
Monitoring
Parameters
• Neuroleptic
Malignant
Syndrome
• Tardive
Dyskinesia
• Hyperglycemia
and Diabetes
Mellitus
• Weight gain
• Akathisia
• Dyslipidemia
None related to youth
Agranulocytosis; seizures; myocarditis; other
adverse cardiovascular
and respiratory effects
None related to youth
None related to youth
None related to youth
Not approved for
depression in under age
18. Increased the risk of
suicidality in short-term
studies in children and
adolescents with major
depressive disorder
and other psychiatric
disorders
• Neuroleptic
Malignant
Syndrome
• Tardive
Dyskinesia
• Hyperglycemia
and Diabetes
Mellitus
• Weight gain
• Akathisia
• Dyslipidemia
• Prolonged QTc
interval
† Dosage recommendations in this table are based on reference # 17 (Jensen, 2010).
‡ There is no current clinical consensus regarding the need for routine ocular evaluations in children and adolescents. Data from animal studies suggest that quetiapine might be associated with increased
risk of cataract development, but this has not been concluded from current evidence in human use.
§ There is no current clinical consensus regarding the need for routine monitoring of QTc interval with use of Ziprasidone in children and adolescents. For additional information regarding EKG monitoring
with Ziprasidone use, please refer to reference # 4 (Blair, 2005).
September 2010
Psychotropic Medication Utilization Parameters
17
Antipsychotics: First Generation (Typical)
Drug
Starting Dose
Literature Based
Maximum Dosage
FDA Approved
Maximum Dosage
for Children and
Adolescents
Schedule
Black
Box
Warning
Chlorpromazine
Generic available
Child
0.275 mg/kg
None related to youth
Adolescent
12.5 mg
Approved for treatment of
severe behavioral
problems in children
(6 months to 12 years)
Two to four times daily
Thorazine®
Chidlren younger
than 5 years
40 mg/day
Children 5-12 years
75mg/day
Adolescent
800 mg/day
Warnings and Precautions
• May alter cardiac conduction
• Sedation
• Orthostatic hypotension
• EPS
• Tardive Dyskinesia
• Neuroleptic Malignant Syndrome
• Use caution with renal disease, seizure disorders, respiratory disease,
and any acute illness in children
• Weight gain
Outpatient Children:
0.25mg/pound every 4-6
hours
Inpatient Children:
200mg/day in older
children
Haldol®
<35 kg:
0.25-0.5mg/
day
≥35 kg:
1 mg/day
<35 kg:
3-4 mg/day
≥35 kg:
10 mg/day
Approved for treatment
of Psychotic Disorders,
Tourette’s Disorder, and
severe behavioral problems in children 3 years
and older
Once to three times
daily
None related to youth
AF
Haloperidol
Generic available
T
Adolescents
800 mg/day
Psychosis: 0.15mg/kg/day
Tourette’s and severe
behavioral problems:
0.075mg/kg/day
• Sedation
• Orthostatic Hypotension
• EPS
• Photosensitivity
• Tardive Dyskinesia
• Constipation
• Dry Mouth
• Tachycardia
• Prolactin elevation
6mg/day
Perphenazine
Generic Available
6-12 years: 6 mg/day
Adolescents:
64 mg/day
Approved for treatment of
psychotic disorders in
12 years and older
Three times a day
Pimozide
Orap®
1-2 mg/day
≤ 12 years
0.2 mg/kg/d
10 mg/day
None related to youth
• EPS
• Tardive Dyskinesia
• Dystonia
• Neuroleptic Malignant Syndrome
• Orthostatic hypotension
• May alter cardiac conduction
• Endocrine changes
• Weight gain
None related to youth
• EPS
• Tardive Dyskinesia
• Dyskinesias
• Dry Mouth
• Constipation
• Prolactin Elevation
• Prolongs QTc interval
64mg/day
DR
Trilafon®
≥ 12 years old
12 mg/day
Approved for treatment of
Tourette’s Disorder in
12 years and older
Once to twice daily
10mg/day
Chlorpromazine and Haloperidol, when prescribed for severe behavioral problems, should be reserved for children with who have failed to respond
to psychotherapy or medications other than antipsychotics.
September 2010
Psychotropic Medication Utilization Parameters
18
Mood Stabilizers
Drug
Initial
Dosage
Target Dose or
Range
Carbamazepine
Generic available
Under 6 years:
10-20mg/kg/
day
Under 6 years:
35mg/kg/day
Carbatol®
Tegretol®
Tegretol® XR
6-12 years:
100mg twice
a day
12 years and
older:
200mg twice
a day
Literature
Based
Maximum
Dosage
FDA Approved
Maximum Dosage
for Children and
Adolescents
Schedule
Approved for Seizure
Disorders in all ages
Immediate
Release two
to four times
a day
Maximum dosages
Under 6 years:
35 mg/kg/day
6-12 years:
400-800mg/day
• CBS
• Electrolytes
Sustained
Release
(XR) twice
a day
6-12 years:
800mg/day
12 years and older:
800-1200mg/day
Baseline
Monitoring
Black
Box
Warning
Warnings and
Precautions
StevensJohnson syndrome
Aplastic Anemia/
Agranulocytosis
• Aplastic Anemia
• Neutropenia
• Hyponatremia
• Induces metabolism
of itself and some
other drugs
• Decreased efficacy of
oral contraceptives
• Teratogenicity
• Stevens-Johnson
Syndrome
12-15 years:
1000 mg/day
Divalproex Sodium
Generic available
250mg/day
500mg-2000mg/day
Lithium
Generic available
Eskalith®
Eskalith®CR
Approved for Seizure
Disorders in 10 years
and older
Frequency:
Day 7
• Weekly until
stable
• q6 months
thereafter
Maximum dose based
upon serum level.
Maximum
dose based
upon serum
level.
Approved for manic
episodes and
maintenance of
Bipolar Disorder in 12
years and older
Two to three
times daily
• Chemistry Panel
• CBC (with platelets)
• LFTs
• Pregnancy test
Hepatotoxicity;
Teratogenicity;
Pancreatitis
Children:
15-20 mg/kg/
day in two to
three divided
doses
Adolescents:
300mg three
time daily (or
900mg/day)
Dose
adjustment based
upon serum level.
Serum level:
0.4-0.6 mEq/L
Note: 300mg Lithium
Carbonate increases
serum level by 0.2 –
0.4mEq/L
Serum level:
0.6 – 1.2
mEq/L
Frequency of
blood level
monitoring:
• Day 7
• Weekly until
stable
• q3 months
thereafter
Serum level:
50-100 mcg/ml
or
60 mg/kg/day
Lamotrigine
Generic Available
Children:
2-5mg/day
Lamictal®
Adolescents:
25mg/day
(increase by
25mg every 2
weeks)
Children:
• with Valproate
1-3mg/kg/day
• with Valproate and
EIAED’s *
1-5mg/kg/day
• Monotherapy
4.5-7.5mg/kg/day
• with EIAED’s
5-15mg/kg/day
Adolescents:
• with Valproate
100-200mg/day
• with Valproate and
EIAED’s
100-400mg/day
• Monotherapy
225-375mg/day
• with EIAED’s
300-500mg/day
Once to
three times
daily
Maximum dose
Serum level:
1.2 mEq/L
DR
Lithobid®
Range:
50-120 mcg/
ml
AF
Depakote®
T
>15 years:
1200 mg/day
Approved for
adjunctive therapy for
Seizure Disorders in
2 years and older
Maximum dose
500 mg/day
• Chemistry Panel
• CBC (with platelets)
• Serum Creatinine
• TFTs
• Pregnancy test
• ECG
Once to
twice daily
initially, then
twice daily
for maintenance
Safety and effectiveness for treatment
of Bipolar Disorder
in patients below 18
years has not been
established
* EIAED’s - Enzyme Inducing Anti-Epileptic Drugs (e.g. Carbamazepine, Phenobarbital, Phenytoin, Primidone)
September 2010
• Hepatotoxicity
• Teratogenicity
• Pancreatitis
• Urea cycle disorders
• Multi-organ hypersensitivity reaction
• Thrombocytopenia
• Withdrawal seizures
• Suicidal ideation
• Polycystic ovaries
Toxicity above
therapeutic
serum levels
• Toxicity above therapeutic serum levels
• Renal function
impairment
• Special risk patients:
those with significant
renal or cardiovascular
disease, severe debilitation, dehydration,
sodium depletion, and
to patients
• Polyuria
• Tremor
• Diarrhea
• Nausea
• Hypothyroid
• Teratogenic
Serious rashes
including
StevensJohnson
syndrome and
asceptic
meningitis
• Dermatological reactions
• Potential Stevens
Johnson Syndrome
• Acute-multi organ
failure
• Withdrawal seizures
• Blood dyscrasias
• Hypersensitivity
• Suicidal ideation
Psychotropic Medication Utilization Parameters
19
Glossary
BMI = Body Mass Index. A measure of body fat based upon height and weight.
CBC = Complete blood count. Lab test used to monitor for abnormalities in blood cells, e.g., for anemia.
Serum creatinine = A lab test used to calculate an estimate of kidney function.
ECG = Electrocardiogram
EPS = Extrapyramidal side effects. These are adverse effects upon movement, including stiffness, tremor, and severe muscle spasm
FDA = U.S. Food and Drug Administration
LFTs = Live function tests
AF
MAOIs = Monoamine Oxidase Inhibitors
T
Hemoglobin A1c = A laboratory measurement of the amount of glucose in the hemoglobin of the red blood cells. Provides a measure of
average glucose over several days.
Prolactin = A hormone produced by the pituitary gland.
DR
TFTs = Thyroid Function Tests
September 2010
Medicaid Managed Care for Foster Children: An Early Report
Summary of a report prepared by the Center for Public Policy Priorities
Children in foster care have a higher prevalence of physical health, behavioral or mental health,
and developmental problems than other children from the same socioeconomic backgrounds.
Approximately 60% of foster children have a chronic medical condition, 25% have three or more
chronic conditions, and between 54% and 80% have diagnosable psychiatric conditions. Senate
Bill 6 in 2005 directed the Health and Human Services Commission (HHSC) to create a new health
care delivery model to provide foster children with comprehensive services, a “medical home,” and
coordinated access to care. As a result, STAR Health, a new Medicaid managed-care model for
foster children, was implemented on April 1, 2008.
In addition, the federal Foster Connections to Success & Increasing Adoptions Act of 2008
requires that states improve access to and coordination of health care for foster children as a
condition of maintaining federal funding. Specifically, states must ensure continuity of care,
establish a medical home, oversee prescription medication, create a schedule for health
screenings, and ensure that medical information is updated and appropriately shared through
mechanisms which may include an electronic health record. With the implementation of STAR
Health, Texas appears to already meet the act’s provisions.
Before STAR Health, foster children were in traditional, fee-for-service Medicaid. Features of
STAR Health include: Immediate Medicaid Eligibility where children qualify immediately upon
entering conservatorship; a Medical Home with an assigned Primary Care Provider; Service
Coordination to help members find providers, schedule appointments, access services, and help
all involved to share information; Service Management for members with ongoing and serious
health care needs; a Health Passport or web-based, electronic health care record; and Help
Lines open continually to get answers to health questions. DFPS excludes certain parties from
accessing the Health Passport, which is HIPAA compliant, online; however, they can view hard
copies at DFPS offices. Information available includes: health care visit history, prescriptions filled,
demographic data including contact information for the child, immunization history, lab results,
allergies, vital signs, and forms. Service coordinators and managers work in two-person teams
with one member experienced in physical health and the other in behavioral health. Service
coordination can be requested by members, providers, caregivers, medical consenters, CPS
caseworkers, or the court system and requests should receive a response within 24 hours.
In general, STAR Health covers medically necessary physical health care, behavioral health care,
dental and vision care, immunizations, hospital care, and prescription drugs. Children eligible for
STAR Health include: children in DFPS conservatorship, including those placed in a relative’s
home; young adults 18 to 22 who voluntarily agree to continue in their foster care placement; and
young adults who age out of foster care and remain eligible for Medicaid who are under age 21
and an income cap. Foster children who are adopted maintain Medicaid eligibility, but once
adoption is completed, move from STAR Health into regular Medicaid. If conservatorship is given
to a parent or relative, children lose STAR Health, but may be eligible for regular Medicaid.
For services in managed care, members must seek care within a defined network of providers.
Managed care organizations authorize or deny requests for certain expensive services in advance
based on medical necessity. They are generally paid a fixed rate paid per-person-per-month to
cover health care services. The STAR Health model transfers financial risk through this system.
The state’s rationale for moving foster children into managed care is to improve services, not to cut
costs. The managed care system through STAR Health, however, removes some control over
medical decision-making from children’s caretakers due to limited provider networks and the ability
to deny requests for certain services.
Although the number of potential providers decreased from all Medicaid providers to those in the
STAR Health network, Superior, the managed care organization, assumed the responsibility to
ensure adequate access for covered services across the state by setting several standards,
including allowable waiting times for appointments, required numbers of network providers within a
geographical area, and allowable percentage of out-of-network claims. Although proximity to
providers is a complaint, a current evaluation of STAR Health shows 90 percent of members can
access providers within distance requirements. Still, the concern heard most from an array of
stakeholders was about the inadequacy of Superior’s network. There has also been confusion
about which providers are in the STAR Health network. Superior was sanctioned for releasing
provider directories with incorrect information. Caretakers can now search for participating
providers using Superior’s online provider search function.
Superior’s provider contracts require Primary Care Physicians (PCP) to assess the medical and
behavioral health needs of members; provide referrals for specialty care; submit forms to the
Health Passport; and be accessible (calls returned with in 30 minutes) 24 hours a day, 7 days a
week. Provider contracts allow specialists to act as a PCP for members with special health care
needs. Members may change their PCP at any time. Superior is required to contract with various
behavioral health providers to meet the needs of members, including providers who specialize in
treating child victims of neglect and physical or sexual abuse. STAR Health behavioral health
providers, following the first 10 behavioral health visits, must get periodic prior authorizations from
the STAR Health HMO for outpatient therapy visits. The required authorizations occur at more
frequent intervals and may receive more scrutiny than under fee-for-service Medicaid.
STAR Health services that require prior authorization from Superior include out-of-network
services and inpatient hospitalizations (except emergencies), certain rehabilitative therapies, visits
to certain specialists, and ongoing outpatient behavioral health care visits. Superior’s provider
handbook notes that it will respond to providers’ requests for prior authorization within 48 hours.
Superior created a pre-appeals process for services requested through prior authorization, where
a service manager will attempt to get additional information. If medical necessity is still in question,
Superior’s medical director or a consulting physician will make at least two attempts to conduct a
peer-to-peer review with the PCP to discuss clinical information or alternative treatment options.
All STAR Health providers are required to comply with Psychotropic Medication Utilization
Parameters for Foster Children. Since these guidelines were released early in 2005, psychotropic
medication usage by foster children has decreased. Compliance is monitored on children age 4
and under on psychotropic medication, children on five or more medications, and children on a
psychotropic medication without a behavioral health diagnosis.
Superior’s contracts with providers require that they testify in court when needed, but the state has
no process to reimburse them for that service which may be a deterrent for provider participation.
By contract, Superior must authorize and reimburse all court-ordered care that is a benefit of
Texas Medicaid. This includes instances when a judge orders care from a specific provider not in
Superior’s network as long as the provider accepts Medicaid. Judges may contact STAR Health
judicial liaisons by calling (512) 466-4102 or sending email to SHPNFC@centene.com.
Need More Information?
The Center for Public Policy Priorities (CPPP) full article can be found at:
www.cppp.org/files/4/351%20Medicaid%20Managed%20Care%20for%20Foster%20Care.pdf
0
Psychotropic Medication Utilization Parameters for Foster Children:
www.dshs.state.tx.us/mhprograms/psychotropicmedicationfosterchildren.shtm
Superior’s STAR Health website: www.fostercaretx.com
DFPS’ STAR Health website: www.dfps.state.tx.us/About/Renewal/CPS/medical.asp
STAR Health contract: www.hhsc.state.tx.us/medicaid/STAR_Health.pdf
Residential Treatment for Children and Youth
Program Participants:
Children and adolescents admitted to RTCs often have long-standing problems that
remain unresolved despite previous attempts at remediation. These children and
adolescents have often displayed a wide variety of diverse symptomatology including
depression, suicide attempts/gestures, anxiety, self-destructive behaviors, psychosis,
eating disturbance, truancy, running away, school phobia, lying, and extreme
negativism. Some children and adolescents are struggling with serious emotional
problems that have developed into patterns of life-threatening or high-risk behaviors
that require intensive intervention in a contained and highly structured environment.
Some children and adolescents are experiencing serious psychiatric disturbances and
are in need of intensive medical intervention in the form of psychotropic medication
and/or ongoing psychiatric monitoring and consultation. Others still, have longstanding relationship problems or have been unable to negotiate basic developmental
stages and need long-term relationship-based treatment to remediate.
Milieu Therapy:
Milieu therapy is a 24 hour daily, therapeutic living environment facilitated by
Residential Counselor staff. Milieu therapy is focused on providing planned structure,
support, routine and a "therapeutic culture" to allow for improved daily living skills,
coping skills, and interpersonal relationship skills. Trust, safety, and respect are core
components of a program's approach.
Family Therapy:
Family therapy is provided on a weekly basis by Master’s level clinicians. The family is
an essential part of successful treatment and a critical factor in the long term success of
children after they leave a program. Families are expected to take an active role in the
treatment process. The goal of family therapy is to assist the family in developing
improved communication and problem solving skills and to learn to more effectively
understanding and meet their child’s unique emotional needs. In addition, families
have the opportunity to participate in parent education and support groups.
Individual Therapy:
Individual therapy is provided to all children and adolescents on a twice weekly basis by
Master’s level clinicians. Intensive individual therapy is a significant component of the
treatment program at Residential Treatment Centers. The goal of individual therapy is
to assist the child or youth in developing an improved understanding of their emotional
and mental health problems, to process and work through past difficulties and traumas,
and to develop skills in effectively communicating their needs and feelings, problem
solving, and coping with their emotional and mental health needs. The individual
therapists coordinate and consult with the Treatment Team to compliment work being
done in other areas of the program. Clients also have many opportunities for informal
counseling interactions with Residential Counselor staff, which serve to enhance the
overall therapeutic focus of the program.
Group Therapy:
Group Therapy is provided to all clients on a twice per week basis. Groups are led or
supervised by Master’s level clinicians and staff. Individuals are assigned to groups
based upon their developmental level and clinical need. Group Therapy is ongoing and
both dynamically and skill oriented. The content of the group is largely determined by
the issues of its members and often involve relationships, parenting and caretaking,
self-esteem, sexuality, and other normal child/adolescent or treatment issues. All
clients may also participate in community meetings, which are process and skills groups
that occur on the living units two times each day. These meetings are generally 45-60
minutes in length and are led by Residential Counselors. The meetings provide clients
an opportunity to discuss issues related to unit functioning, rules, emotional regulation,
self-soothing, and interpersonal relationships. Topics may include: Social Skills,
Problem Solving Skills, Conflict Resolution Skills, Relaxation Skills, Independent Living
Skills, Gender-Specific Issues, Sexual Health, Chemical Health, and Self-Esteem.
Psychiatric Consultation and Medication Management:
All children and youth see a Board Certified Child and Adolescent Psychiatrist as part
of the initial evaluation process and on an ongoing basis. Frequency of ongoing
psychiatric contact depends on each client’s specific needs. Clients are seen minimally
on a monthly basis and can be seen as frequently as weekly if indicated. Most clients
at Residential Treatment Centers take psychoactive medications.
Treatment Plans for Mental Health
Therapy is a process in which someone
receives treatment for mental health issues.
A treatment plan is necessary to pinpoint the
exact issues being treating and the ways in
which they will be addressed. It sets specific
goals that allow both provider and client to
access progress. It acts as an important road
map, providing guidance on the road to the
goals and instructions on how to reach them. Take notes that can be used to fill out the therapy plan form.
Six Steps to a Successful Treatment Plan:
Step 1: Treatment Goals
Treatment goals should be set with the client. These goals should be as specific as
possible. For example, if you are treating someone with anxiety disorder, do not use a
general goal like "Reduce anxiety." Come up with specific, measurable goals like "Client
will be able to comfortably approach and talk to strangers" and "Client will attend social
gatherings rather than staying home due to anxiety."
Step 2: Action Steps
Specific steps should be developed for each of the goals. The steps should be specific
actions that the client can take to accomplish each goal with a defined series of actions
within a specified timeframe.
Step 3: A Client-Centered Plan
Steps should be discussed with the client, making appropriate changes if needed. In
client-centered treatment, the steps should take the client's abilities and limitations into
consideration as well as motivation and ownership. They should allow the client to have
small successes that act as the foundation for bigger ones.
Step 4: Timeframe
A timeframe for the treatment plan should be created. The client and treatment provider
should set a target to accomplish each goal. Remember, each individual step can also
have a timeframe if appropriate. It is important to indicate how often progress will be
assessed. Usually this is done at each counseling session, but that can be variable.
Step 5: Documentation
The treatment plan should be recorded on a form used the treatment provider or agency.
There are generally standardized forms for treatment planning as well as progress notes.
It is important that no treatment plan be applied in a “cookie cutter” fashion without
individualizing the treatment to the presenting problem and client’s needs.
Step 6: Treatment Teams
Those serving on a client’s treatment team, especially with psychiatric hospitalization or
residential treatment, may all access and add to the treatment plan so that it will
represent the entire treatment process and measurable progress. FLORIDA DEPARTMENT OF JUVENILE JUSTICE
SAMPLE
INITIAL MENTAL HEALTH TREATMENT PLAN
Child or Youth’s Name_____________________________________
DOB________________ Sex______ Race______
Facility Name ___________________________________________
1. Reason for Mental Health Treatment:
2. Initial Diagnosis or Presenting Symptoms:
Initial DSM-IV-TR Diagnoses
Axis I
Axis II
Axis III
Axis IV
Axis V (GAF)
Presenting Symptoms
3. Initial Treatment Methods: (Describe treatment methods, duration, amount and frequency of mental health
services. For children or youths receiving psychiatric care, record: 1. Psychotropic medications currently
prescribed; and 2. Frequency of monitoring by a psychiatrist).
__
__
4. Initial Treatment Goals and Objectives
Goal:
Objective:
Goal:
Objective:
Goal:
Objective:
Youth’s Signature/Date
Parent/Guardian’s Signature/Date
Mental Health/Substance Abuse Clinical Staff’ Signature/Date
Treatment Team Member Signature/Date
Licensed Mental Health Professional’s or CAP Signature/Date
Treatment Team Member Signature/Date
MHSA 015
August 2006
P.O. Box 7338 • Madison, WI 53707-7338
45 Nob Hill Road • Madison, WI 53713-3959
Voice/TDD: (608) 276-4000 • (800) 279-4000
Fax: (608) 661-6706 • Web site: www.weatrust.com
Outpatient Mental Health Treatment Plan
Please complete this entire form and fax
to the attention of Administrative Assistant, Behavioral Health, at (608) 661-6706
Clinic:
Tax ID:
Clinician Name, Credentials:
Clinic Phone:
Address:
Patient Name:
City:
Subscriber ID:
State:
Zip:
Fax No.:
Patient DOB:
First date of service: _________________
Authorization requested from date: _________________
Anticipated closure date:
DSM IV Diagnosis—Axis I through V:
Axis I:
Code(s):
Axis II:
Code(s):
Axis III:
Axis IV (specify):
Highest GAF past year:
Axis V: Current GAF:
Current Psychiatric Status (mark where applicable):
Symptoms/Problems
Depressed mood
Obsessions/compulsions
Anxiety
Impulsiveness
Somatic complaints
Poor judgment
Sexual issues
Impaired concentration
Appetite disturbance
Irritability
Hyperactivity
Sleep disturbance
Delusions
Paranoia
Panic attacks
Hallucinations
Phobias
Impaired memory
Alcohol abuse
Opiate abuse
Prescription medicine abuse
Polysubstance abuse
Initial date:
Mild
Moderate
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
Severe
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
Current date:
Mild
Moderate
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
Severe
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
Over ¼
Current Psychiatric Status—Risk Assessment (mark where applicable):
Initial date:
Mild
Moderate
Suicidality
Homicidality
Violence
‰
‰
‰
‰
‰
‰
Severe
Current date:
Mild
Moderate
‰
‰
‰
‰
‰
‰
Severe
Thought
Plan
Means
Method
Gesture
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
‰
Current Medications (Please list name, dose, date started, and compliance.):
Current medications are prescribed by:
‰ Psychiatrist
‰ Primary care provider
‰ Other:
Narrative Summary (Please note current level of functioning in life domains, progress made, and symptoms still in need of
improvement.):
(If additional space is needed, please attach your notes to this form.)
Treatment Approach(es):
‰ Cognitive/behavioral
‰ DBT
‰ Solution-focused ‰ Psychoanalytical ‰ Interpersonal
‰ Other:
Covered Treatment(s): Only the following procedure codes will be considered for preauthorization. Extended individual
psychotherapy (beyond 50 minutes, such as 90808) requires a separate preauthorization.
Total # of Sessions
Frequency of Sessions
A. Medication management:
2
Medication mgnt.:
90862 and/or 90805
(please circle one)
4
‰ ‰
6
8
10
12
‰ ‰ ‰
‰
Other
Weekly
1 in 2 wks
(biweekly)
Monthly
‰
‰
‰
Weekly
1 in 2 wks
(biweekly)
Monthly
Other
B. Psychotherapy with/without medication management:
2
Individual or family
Group
With medication mgmt.
(up to 50 minutes)
4
6
8
10
12
Other
90804, 90806, 90847
90853
‰ ‰
‰ ‰
‰ ‰ ‰
‰ ‰ ‰
‰
‰
‰
‰
‰
‰
‰
‰
90807
‰ ‰
‰ ‰ ‰
‰
‰
‰
‰
Other
Notes to patient: Approval of this treatment plan does not guarantee payment of benefits. Final determination is based
upon plan eligibility, applicable deductibles, coinsurance, copayments, and plan limits. By signing below, you
acknowledge that you have been educated about your diagnosis, its cause, and its nature and duration, and you
understand your consumer role in treatment. Your signature below is requested but is not required for preauthorization of
services.
_______________________________________________________
(Patient’s/Guardian’s Signature if Patient is a Minor)
Date
___________________________________________________________________
(Provider’s Signature)
Date
MHS 2970-650-0207(W)
CONFIDENTIAL
Mental Health Treatment Plan
Area of Need:
Present Level:
Measurable Long-Term Goal:
Parents will be informed of progress
 Quarterly
 Trimester
 Semester
 Other:_________
How?
 Annotated Goals/Objectives
 Other: ____________________
Benchmark/Short-Term Objective:
Periodic Review Dates
1. ________________
2. ________________
3. ________________
4. ________________
Progress Toward Goal
1. ___________________________
2. ___________________________
3. ___________________________
4. ___________________________
Sufficient Progress to Meet Goal
 Yes  No ___________________
 Yes  No ___________________
 Yes  No ___________________
 Yes  No ___________________
Date:
 Achieved
 Reviewed
Person(s) Responsible:
Benchmark/Short-Term Objective:
Date:
 Achieved
 Reviewed
Person(s) Responsible:
Area of Need:
Present Level:
Measurable Long-Term Goal:
Parents will be informed of progress
 Quarterly
 Trimester
 Semester
 Other:___________
How?
 Annotated Goals/Objectives
 Other: _____________________
Benchmark/Short-Term Objective:
Periodic Review Dates
1. ________________
2. ________________
3. ________________
4. ________________
Progress Toward Goal
1. ___________________________
2. ___________________________
3. ___________________________
4. ___________________________
Sufficient Progress to Meet Goal
 Yes  No ___________________
 Yes  No ___________________
 Yes  No ___________________
 Yes  No ___________________
Date:
 Achieved
 Reviewed
Person(s) Responsible:
Benchmark/Short-Term Objective:
Date:
 Achieved
 Reviewed
Person(s) Responsible:
______________________________________
______________
______________________________________
Student Signature
Date
Signature of Parent
__________________________________________
Signature of Mental Health Services Representative
______________
Date
______________
Date
Diana Browning Wright, Behavior/Discipline Trainings, 2002
MH Treatment plan Sample 3
CONFIDENTIAL
Date:
Student:
Type of Service:
Diana Browning Wright, Behavior/Discipline Trainings, 2002
Start Date:
Duration:
MH Treatment plan Sample 3
Mental Health Treatment Plan
Patient Name:
Patient ID#:
Date:
Problem #1:
Current Impairments/
As Evidenced By:
Long Term Goal:
Short Term Objectives:
Interventions:
Referrals/Resources Recommended:
Bibliotherapy
Journaling
Adjunct Treatment
Support Group/Community Resource
Other Homework
Addiction/Dependency Referral
Psychiatrist
Support Group/Community Resource
Other Homework
Addiction/Dependency Referral
Psychiatrist
Problem #2:
Current Impairments/
As Evidenced By:
Long Term Goal:
Short Term Objectives:
Interventions:
Referrals/Resources Recommended:
Bibliotherapy
Journaling
Adjunct Treatment
Anticipated Frequency of Visits: ___Weekly
Biweekly
Monthly
Other:
Anticipated Length of Treatment Episode: ___________________________
This plan has been discussed with the patient who
reasons
agrees with the plan
Patient/Parent/Guardian (optional)
Date
Practitioner Signature (required)
Date
objects to the plan for the following
Revised 5/7/98
Ask if provider has a
mechanism to refer for a
second opinion.
No
Ask why diagnosis is different
from previous diagnoses (if
applicable.)
No
Ask how diagnosis has ruled
out other possibilities like a
reaction to trauma, grief, loss
No
Ask how diagnosis reflects
presenting problem
No
Do I understand the
diagnosis?
Yes
Yes
Yes
Yes
Ask about inclusion of family
members/siblings
Ask about frequency of
different therapies
What methods of treatment
are prescribed?
Do I understand the
treatment process?
Advocacy Questions Tree for Provider
Yes
Ask about specific needs of
the child
Ask to be involved in
staffings / team meetings
Ask how the provider will
measure progress
Do I understand
how to monitor/
advocate?
Advocating For Children with Emotional Problems
Some nine million children have serious emotional problems at any point in time. When parents,
advocates or teachers suspect that a child may have an emotional problem, they should seek a
comprehensive evaluation by a mental health professional specifically trained to work with children and
adolescents.
Throughout the evaluation process, you should be directly involved and ask many questions. It's
important to make sure you understand the results of the evaluation, the child's diagnosis, and the full
range of treatment options. If you are not comfortable with a particular clinician, treatment option, or are
confused about specific recommendations, ask the questions you need to ask and, if needed, consider a
second opinion.
You may want to ask the following:









What are the recommended treatment options for the child?
How will family be involved with the child's treatment?
How will we know if the treatment is working?
How long should it take before I see improvement?
Does the child need medication?
What are potential side effects of any medication?
How will we know if the medication is working?
What should I do if the problems get worse?
What are the arrangements if I need to reach you after-hours or in an emergency?
You may also need to advocate for the child to be seen in a timely way, by the most appropriate clinician.
Most insurance plans now include some form of managed care, which may utilize provider panels with
few mental health professionals. However, many states now have laws concerning reasonable access to
specialists. If you have problems or questions, try calling the Department of Insurance, the Patient
Ombudsman/Advocate, or the Department of Consumer Affairs at the insurance company.
Depending on the nature of the child's problems, it may also be important to involve the school,
community agencies, and/or juvenile justice system. In addition, it may be helpful to learn how to access
other support services such as respite, parent skill building, or home-based programs. Local advocacy
groups can also provide valuable information, experience and support.
Although serious emotional problems are common in childhood and adolescence, they are also highly
treatable. By advocating for early identification, comprehensive evaluation and appropriate intervention,
you can make sure children get the help they need, and reduce the risk of long term emotional difficulties.
For more information about advocacy, contact:
National Alliance of the Mentally Ill
Colonial Place Three (703) 524-7600
2107 Wilson Blvd-3rd Floor
Arlington, VA 22201
http://www.nami.org
National Mental Health Association
(703) 684-7722
1021 Prince Street
Alexandria, VA 22314-2971
http://www.nmha.org
Copyright ©2009 - American Academy of Child Adolescent Psychiatry. All Rights Reserved.
Checklist: Advocating for a
child/youth placed in a RTC
RTCs are not an appropriate long-term placement. Will the RTC focus on treatment on the issues that
brought them into care or will they focus on current issues that arise during placement?
For children in foster care, there is often no continuity of services. Have I kept a record or can I now
retrieve a copy of all previous treatment plans and if treatment was effective as well as what medications
were prescribed and taken and if medications were effective?
Good communication is key to effective advocacy. Am I in regular contact with the case manager,
therapist, teacher and other pertinent staff at the RTC? Do I know when the next “staffing” or “team
meeting” is scheduled and if I can attend in person or via conference call?
Getting the big picture is often difficult when multiple people serve on the treatment team. Do members
of the interdisciplinary team have the same information? Have the same or different opinions? Observe
the same or different behaviors? Have consistent notes/reports?
The child/youth placed in a RTC may be cut off from family, siblings, relatives, previous caretaker. Have I
established how often I will: visit, call, send cards and letters.
The treatment modalities (such as individual therapy, group therapy, family therapy) may vary at each
RTC. What is being offered to the child/youth? What is the frequency of each? Is it adequate to address
their issues and prepare them for discharge?
Medication prescribed to children/youth in foster care should be closely monitored. Do I have a list of
their current medications, who prescribed them, dosage, and understand what condition each medication
was prescribed to treat?
An RTC is a restrictive, institutionalized setting. This does not constitute a “normal” life for a child or
youth. How can I advocate for activities, relationships, social supports, education that will normalize life
for the child/youth.
Direct care staff at a RTC spend the most time with residents. They are also the least trained, skilled and
educated members of the treatment team. Direct care staff or shift staff may be taught how to restrain a
child without understanding how to de-escalate or diffuse a child in distress that would avoid restraint. I
need to understand what kind of physical restraint system is used at the RTC and how long it each incident
is to last.
Some children and youth may be at increased risk for abuse in this setting. Do I have open-ended
questions (not leading questions) I can ask of the child/youth about their experience in the RTC?
Any placement change is disruptive. While I want to see the child/youth in the least restrictive
environment possible, if they need continued service at the RTC but are at risk of discharge because their
behaviors are improved, can I partner with the RTC to advocate a placement change decision be made
based on a clinical recommendation and not the child’s LOC?
Does the child/youth know their rights?
Checklist: Advocating for
Special Needs
Aging Out
Will a youth in this RTC be offered services to help them transition such as: Preparation for Adult Living
(PAL) classes, Circle of Support, Transition Plan Meeting?
Is the RTC going to assist in helping the youth find a place to live upon discharge?
What accommodation can the RTC make so that I can help the youth with preparation for independent
living?
Will the teacher discuss a GED certificate, application to college or vocational school, financial aid and
tuition waivers?
Will the youth have the needed documents and identification card upon discharge?
Education
What is the quality of the educational program at the RTC? How does their school rank with the state
(unacceptable, acceptable, recognized, exemplary)?
What method will the teacher use to understand the current academic level of functioning of the
child/youth?
Will they have an Independent Education Plan (IEP) to move them from the current level of functioning to
age appropriate performance (if possible)?
What services are available (for special education, tutoring, speech therapy, etc.)?
Will they hold an ARD?
How will the plan to transition the child to the next school? What contact will they have with that school?
Disabilities
What medical facility is closest to the RTC?
What MD do they use for medical visits, emergencies, services?
How/when are referrals made?
Is the MD a pediatrician?
How does the RTC plan to accommodate for a particular disability?
Is occupational therapy available?
What specialists are available in the area and do they take the child/youth’s insurance?
Tips for Providing Experiential Life Skills Training
in Residential Treatment Settings
All youth growing up in foster care need to receive hands-on training in life skills to help
prepare them for their transition to adulthood. However, when youth are living in RTCs or
other structured settings, it can take some creativity to provide experiential activities that meet
the needs of youth within the setting, particularly youth who require a more restricted
environment. Activities should be individually tailored to a youth's skills and abilities and can
include practical skills. Here are some tips for activities to help you start thinking of ways to
provide experiential activities.
These tips are a product of the House Bill 1912 (81st Legislative Session) workgroup and they
were developed to help caregivers fulfill the requirement of providing or assisting foster youth
age 14 or older in obtaining experiential life-skills training to improve their transition to
independent living.
FOOD AND MEALS

Preparing Food: In some residential settings, only people who have received Food
Handler’s Certification are allowed to prepare food in the facility kitchen. Even if this is
not the case, it may not be in the best interest of the youth to expose them to kitchen
utensils and appliances that may be used in a harmful manner. However, youth need to
learn how to prepare their own food. One way to provide an experiential activity in
food preparation is to take the lesson outside of the kitchen to a classroom or other
appropriate setting and prepare something simple that does not require cooking, such
as trail mix or smoothies. A simple recipe can be utilized to teach how to use recipes
and follow written directions, such as on packages of ready-to-prepare foods. Youth can
receive experience in using measuring cups and spoons and mixing bowls. This is also a
great time to discuss nutrition.

Meal Planning: Youth can find a recipe they like in a cookbook, online, or in a magazine.
They can make a list of ingredients to plan a meal for an individual and then another for
making a meal for a group. If youth are able to go grocery shopping to purchase items,
have them take a calculator and budget along with the list. Challenge: give each youth a
few dollars to utilize for a meal and go to the grocery store with a group of youth. They
can choose to buy items and make their own meal or put their money together to make
a nicer meal for the group. Make a weekly meal menu for the home and list all the
ingredients needed to prepare the meal. Go to the store and look at prices and
combinations of food items to see if there are ways to lower expenses or utilize
ingredients in several meals. If youth are unable to go to a public grocery store, have
them create the menu and list ingredients needed. They can then look in newspaper
ads or on-line to get ideas about how much the meals may cost to prepare.
6/17/2010

Taking Training on Meals to the Next Level: An ideal way to teach about food
preparation, meals and etiquette is to do so in a simulated (or real) kitchen and dining
room. Some RTCs have life skills buildings that contain kitchen and dining areas that
include all of the standard cooking appliances and supplies needed to prepare a meal as
well as all of the serving ware needed to appropriately set the dining table for a nice
meal. In addition to learning about cooking, nutrition, and meal planning, youth also
can be taught dining etiquette. If your RTC is unable to provide these facilities, think
about other ways that etiquette and other lessons could be taught.
HOUSEKEEPING

Laundry: If laundry facilities are available onsite that youth may use, teach the youth
how to do laundry and give them the responsibility of taking care of their own laundry.
One way to do this is for each youth to have an assigned laundry day. On that day, staff
assist the youth with doing their laundry to the extent that each youth needs assistance.
With youth who are just beginning to do laundry, who have never received formal
instruction, or who need more supervision, staff should guide youth completely through
the laundry process, teaching them how to sort clothes, appropriately fill the washer,
use detergent, etc. The youth should also be taught how to put their clothes away after
they have been cleaned, folding or hanging as appropriate to the type of apparel. As
youth become more competent in their laundry skills, they can have more autonomy in
doing the laundry with less and less assistance from staff. If the RTC does not have a
laundry room onsite that youth can use, youth can be taken on an outing to a
Laundromat to learn how to do laundry.

Cleaning: In most RTCs, youth are given responsibility for making their own beds and
helping to clean their living environment, such as sweeping and cleaning the bathroom.
However, if this is not happening, it may be a good idea to incorporate such chores into
the routine so that youth develop skills in housekeeping and learn to take responsibility
for the cleanliness of their home.

Organization: Youth often need to be taught how to keep their possessions in a neat
and organized manner. This skill can best be taught one-on-one with the youth and a
staff person, intern or volunteer. This person can help the youth sort through their
possessions and organize them in their closet and other storage spaces. It is important
to ensure that this experience is a learning opportunity for the youth, teaching them
how to think through how to organize, rather than the assistant just doing the
organizing for the youth. During this process, the assistant can aid the youth in
determining that some items are no longer of use and should be gotten rid of, thus
developing an important skill in managing one’s possessions. However, considering the
particular situation of youth in foster care, it is not uncommon for youth to have a
strong attachment to their possessions and have great difficulty in parting with them.
Youth can be taught how to appropriately care for items of sentimental value by giving
6/17/2010
them the opportunity to put such items in an album or treasure chest. This can also
make for a good therapeutic activity.
FINANCIAL MANAGEMENT
 Allowances: If youth receive an allowance, create a log for keeping track of their money
and have them write down any they spend. This will help prepare them for using a
checkbook register and help them learn to manage their money.

Responsible Spending: Create posters or pictures of household items, hygiene items,
luxury items, and other necessities with prices attached. Have youth “go shopping” with
a limited amount of money. You can even use Monopoly money for fun. Someone can
play “cashier” to learn about making change. Youth can learn about the differences
between “wants” and “needs” and how to prioritize certain items. Discuss fine tuning
shopping experiences, such as making lists before you go and/or how to utilize coupons.

Budgeting: Utilize mock check books and mock monthly budgets to help youth
understand how to keep track of income and expenditures. Youth can prepare a budget
for when they live on their own by giving them information about average wages for
starting out jobs and the average costs of typical budget items, such as rent, utilities, cell
phone bills, food, car insurance, child care, etc. Youth can even help find information
about wages and costs by looking at advertisements and other publications and by
asking adults who are willing to share the information.

Banking: Teach about different types of bank accounts and the difference between
debit and credit. Teach youth how to choose a bank and how to open checking and
savings accounts. If appropriate and allowable, have youth open an account.

Credit Cards: Bring in examples of credit card applications, and go over the “fine print.”
Help youth calculate interest charges and other fees.

Taxes: Bring in mock W-2 forms and 1040EZ forms, and show youth how to complete
and file simple federal income taxes using the paper forms or online. Inform youth of
community agencies where they can receive free assistance in completing their taxes.
EMPLOYMENT

Job Applications: Provide youth with the opportunity to practice filling out job
applications. You can create a mock application or pick up some real applications from
businesses for them to practice filling out.

Interviews: Create role-plays of mock interviews. Allow youth to dress up for the
“interview” and make mock follow up contacts to potential employers.
6/17/2010

On-the-Job Skills: Role-play difficult situations with customers or managers and how to
maintain appropriate interactions. Teach basic job maintenance skills such as being on
time, calling if you are going to be late, and giving notice if you intend to terminate.

Resumes: Assist youth in making a resume. Word processing software, such as
Microsoft Word, includes resume templates that make formatting a resume easy. There
are also many resources available online to help in creating a resume.
PERSONAL DEVELOPMENT

Time Management: Youth can be taught how to prioritize the activities that they need
to do and how to make a schedule for their day. They can also be taught how to utilize
a calendar or planner to help them plan ahead. These skills can be taught as a group
activity or one-on-one.

Leadership Skills: A great way for youth to develop their leadership skills and to feel
that they are able to have a voice in the RTC is to have a Residents’ Council. Criteria
should be established to determine eligibility for participation in the council, and there
should be policies outlining lengths of council terms, participation expectations, how
council members input will be utilized and other important information.

Peer Mentoring: A peer mentoring program can be implemented at the RTC in order to
help youth build their leadership skills and feel that they are being of help to others
while also providing an opportunity for residents to receive additional attention and
support. Guidelines should be established to determine eligibility to be a peer mentor
and to outline the peer mentor’s roles and responsibilities, such as ensuring that peer
mentors report to staff if their mentee has informed them of any safety-related issues.
SOME MORE TIPS

Have youth apply for a library card and learn how to borrow books from the library.

Have youth complete training in First Aid and CPR.

Have youth take a driver’s education class.

If appropriate, allow and encourage youth to get part-time jobs. If they are unable to
leave the RTC campus, perhaps jobs could be made available on campus.
Please note that these activities are just some suggestions to get you started on your journey of
providing experiential life skills activities to youth in your care. The list is not comprehensive,
and caregivers are not required by DFPS to provide these specific experiential activities. If you
6/17/2010
have ideas for other experiential activities or tips to include on this list, please contact DFPS at
gaye.vopat@dfps.state.tx.us.
6/17/2010
Resources to Aid Caregivers in Providing Experiential
Life Skills Training to Foster Youth
The resources listed below are just some suggestions to get you started on your journey of providing
experiential life skills activities to youth in your care. This list is a product of the House Bill 1912 (81st
Legislative Session) workgroup and were developed to help caregivers fulfill the requirement of
providing or assisting foster youth age 14 or older in obtaining experiential life-skills training to improve
their transition to independent living.
This list is not comprehensive, and caregivers are not required by DFPS to use any of these resources.
The materials referenced below contain information created and maintained by other government,
public and private organizations and are provided for the user's convenience. i
If you have ideas for other materials to include on this list, please contact DFPS at
gaye.vopat@dfps.state.tx.us .
Life Skills Training Resources
Texas Youth Connection web site: http://www.dfps.state.tx.us/txyouth/default.asp
DFPS Transitional Living Services Information
http://www.dfps.state.tx.us/Child_Protection/Transitional_Living/default.asp
Ready, Set, Fly! A Parent’s Guide to Teaching Life Skills by Casey Family Programs - Available in
print and also online at http://www.caseylifeskills.org/pages/res/rsf%5CRSF.pdf)
Casey Family Programs list of free web resources:
http://www.caseylifeskills.org/pages/res/res_ACLSAGuidebook.htm#5
Casey Family Programs comprehensive list of resources, including those available for purchase:
http://www.caseylifeskills.org/pages/res/res_ACLSAGuidebook.htm
“50 Things You Can Do to Help Someone Get Ready for Independent Living”
http://www.hss.alaska.gov/ocs/IndependentLiving/Docs/RS%2050%20Things.pdf
“Life Skills Inventory: Independent Living Skills Assessment Tool”
http://www.dshs.wa.gov/pdf/ms/forms/10_267.pdf
Independent Living Books and DVDs by Social Learning
http://www.sociallearning.com/catalog/topics/lifeskills/independentliving.html;jsessionid=a8boZGg48se5
“Truth About Drugs” DVD http://store.discoveryeducation.com/product/show/51960
“Truth About Drinking” DVD http://store.discoveryeducation.com/product/show/53563
6/17/2010
1
“Truth About Sex” DVD http://store.discoveryeducation.com/product/show/48582
FosterClub http://www.fosterclub.com/
Retailers of Life Skills Training Resources
National Resource Center of Youth Services http://www.nrcys.ou.edu/catalog/
National Independent Living Association
http://www.nilausa.org/membersonly/memresourcesn.htm
Daniel Memorial http://www.danielkids.org/sites/web/store/product.cfm
Youth Communication http://www.youthcomm.org/
Social Learning http://www.sociallearning.com/
Discovery Education http://www.discoveryeducation.com/
Training for Caregivers
“Teaching Moments: How Foster Parents Can Teach Independent Living Skills To Teens” DVD
http://www.sociallearning.com/catalog/items/DVD7316.html;jsessionid=adIWbottIDV9
Foster Care and Adoptive Community Training:
http://www.fosterparentstest.com/store/index.htm
“Teaching Essential Life Skills to Children of All Ages”
“Teaching Independence & Keeping Fragile Kids Safe”
“Preparing for Post High School Education”
“Enhancing Independence Through Recognizing and Improving Job Skills”
“Money Skills”
“Sexually Transmitted Diseases: What You Need To Know”
“Health Issues”
i
DFPS does not control or guarantee the accuracy, relevance, timeliness or completeness of this outside
information. Further, the inclusion of references to particular materials and/or of links to particular
organizations or sites is not intended to reflect their importance, nor is it intended to endorse any views
expressed, or products or services offered on these outside sites, or the organizations sponsoring the
sites.
6/17/2010
2
Printer-friendly version
Print using your browser ‘Print’ button
<< Click the browser ‘Close’ button to move on
Module III. Unit 1: Activity 3 – Making Contact with the School
A Tip Sheet for Effective Educational Advocacy
Things to consider doing:
1. Initiate contact with the education provider starting at the “top.” It is
considered common courtesy in the education community for “outsiders” to
initiate telephone contact with the principal first. (This was addressed in
Module II.)
2. Always wear a photo ID badge or carry a photo ID to present at the school or
agency office, AND always check in at the office.
3. Be prepared to present the Order of Appointment from the court.
4. Be prepared to explain the role of a CASA/GAL volunteer. It may be important
to explain your role several times to several educators in the process
(principal, teacher, social worker, school psychologist, at special education
team meetings, etc.). It might be helpful to carry some brochures.
5. Think of the time of day you might contact a teacher. Ask him or her what is
convenient and whether he or she prefers to be contacted by phone or e-mail.
Teachers have responsibilities beyond the classroom, i.e., lunch duty,
committee meetings, etc.
6. Tap into other resources within the school, which include school social
worker, school counselor, and school psychologist.
7. Ask if the parent(s)/guardian(s) are involved in educational decision-making,
and, if not, advocate for the child to be assigned an educational
surrogate/advocate.
8. Get to know the school personnel on a friendly basis. Allow the school to
consider the CASA/GAL volunteer as a resource who is interested in the child.
Be personable! When you present yourself in a professional and easygoing
manner, opportunities for collaboration will be greater.
9. Check in with teachers regularly, not just when there’s a problem or when
there is an upcoming meeting.
National CASA E-Learning – 11.05
10. Let the school know you are interested in this student and will follow up on
important issues.
11. Go over old school reports and assessments. Ask questions where you need
clarification. If a child was in another school for a long period of time
(perhaps before going into foster care), make contact with that school and
request records and information.
12. If a problem arises, always ask for and listen to the school’s side of the
issue.
13. Request that the school notify you in advance so that you may attend
meetings applicable to the child (team meetings, IEP meetings, etc.).
14. Discuss the child’s educational status with the child’s caseworker and
include this information in your court report.
15. Ask the child how he or she is doing in school and include that information in
your court report.
16. Note if behavior difficulties at school can be correlated with other issues in
the child’s life.
17. Facilitate communication to best serve the child within the context of your
volunteer role.
Things to consider avoiding:
1. Making “You should…” types of statements to education providers.
2. Becoming too adversarial. Don’t make meetings seem too much like a legal
proceeding.
3. Badmouthing the child’s family or home situation. Rise above the temptation
to join in with such gossip, even if you hear others doing it.
4. Sharing information you get from one education source with another
education source, even within the same building. For example, the school
psychologist or counselor may share information with the CASA/GAL
National CASA E-Learning – 11.05
volunteer that is not to be shared with the teacher. If such confidentialities
are breached, it will be difficult to enlist friendly cooperation in the future.
However, your sources should be aware that a CASA/GAL volunteer cannot
keep secrets from the court.
5. Signing papers in the school setting regarding the child, such as medical
status, permission to test, or school transfers. That is the job of the
parent/guardian or educational surrogate/advocate. However, you may be
asked to sign forms indicating attendance at some school meetings.
6. Making educational recommendations that don’t fit with recommendations of
the education team at school (especially as related to special education).
7. Dropping in at the school. Always call in advance to request an appointment
or, at the very least, to notify the staff that you will be visiting.
Source: Washington State CASA and TeamChild®
National CASA E-Learning – 11.05
Printer-friendly version
Print using your browser 'Print' button
<< Click the browser 'Close' button to move on
Module IV. Unit 3: Activity 4 – Asking the Right Questions:
A Judicial Checklist To Ensure That the Educational Needs of
Children and Youth in Foster Care Are Being Addressed
General Education Information
Enrollment
ƒ Is the child or youth enrolled in school?
o At which school is the child or youth enrolled?
o In what type of school setting is the child or youth enrolled (e.g.,
specialized school)?
ƒ How long has the child or youth been attending his/her current school?
o Where is this school located in relation to the child’s or youth’s
foster care placement?
ƒ Were efforts made to continue school placement, where feasible?
ƒ If currently not in a school setting, what educational services is the child or
youth receiving and from whom?
o Is the child or youth receiving homebound or home-schooled
educational services?
o If Yes: Who is responsible for providing educational materials and
what information is available about their quality?
o If Yes: How frequently are educational sessions taking place?
o What is the duration of each session (e.g., how many hours)?
Provision of Supplies
ƒ Does the child or youth have appropriate clothing to attend school?
ƒ Does the child or youth have the necessary supplies and equipment (e.g.,
pens, notebooks, musical instrument) to be successful in school?
Transportation
ƒ How is the child or youth getting to and from school?
ƒ What entity (e.g., school, child welfare agency) is responsible for providing
transportation?
Attendance
ƒ Is the child or youth regularly attending school?
ƒ Has the child or youth been expelled, suspended, or excluded from school
this year/ever?
o If Yes: How many times?
o Have proper due process procedures been followed for the
expulsions, suspensions, or exclusions from school?
National CASA E-Learning 11.05
What was the nature/reason for the child’s or youth’s most recent
expulsion, suspension, or exclusion from school?
o How many days of school will the child or youth miss as a result of
being expelled, suspended, or excluded from school?
o If currently not attending school, what educational services is the
child or youth receiving and from whom?
ƒ How many days of school has the child or youth missed this year?
o What is the reason for these absences?
o What steps have been taken to address these absences?
o Has the child or youth received any truancies, and, if so, for how
many days?
o Has the child or youth been tardy, and, if so, how many times?
o
Performance Level
ƒ When did the child or youth last receive an educational evaluation or
assessment?
o How current is this educational evaluation or assessment?
o How comprehensive is this assessment?
ƒ At which grade level is this child or youth currently performing? (Is the child
or youth academically on target?)
o Is this the appropriate grade level at which the child or youth
should be functioning?
o If No: What is the appropriate grade level for this child or youth?
ƒ Is there a specified plan in place to help this child or youth
reach that level?
ƒ What is this child’s or youth’s current grade point average?
o If below average, what efforts are being made to address this
issue?
ƒ Is the child or youth receiving any tutoring or other academic supportive
services?
o If Yes: In which subjects?
Tracking Education Information
ƒ Does this child or youth have a responsible adult serving as an educational
advocate?
o If Yes: Who is this adult?
o How long has this adult been advocating for the child’s or youth’s
educational needs?
o How often does this adult meet with the child or youth?
o Does this adult attend scheduled meetings on behalf of the child or
youth?
o Is this adult effective as an advocate?
ƒ If there is no designated educational advocate, who ensures that the child’s
or youth’s educational needs are being met?
o Who is making sure that the child or youth is attending school?
o Who gathers and communicates information about the child’s or
youth’s educational history and needs?
o Who is responsible for educational decision-making for the child or
youth?
National CASA E-Learning 11.05
Who monitors the child’s or youth’s educational progress on an
ongoing basis?
ƒ Who is notified by the school if the child or youth is absent (i.e., foster
parent, caseworker)?
ƒ Who could be appointed to advocate on behalf of the child or youth if his or
her educational needs are not met?
o
Change in Placement/Change in School
ƒ Has the child or youth experienced a change in schools as a result of a
change in his or her foster care placement?
o If Yes: How many times has this occurred?
o What information, if any, has been provided to the child’s or youth’s
new school about his or her needs?
o Did this change in foster care placement result in the child or youth
missing any school?
o If Yes: How many days of school did the child or youth miss?
ƒ Have any of these absences resulted in a truancy petition?
o Were efforts made to maintain the child or youth in his or her
original school despite foster care placement change?
Health Factors Impacting Education
Physical Health
ƒ Does the child or youth have any physical issues that impair his or her
ability to learn, interact appropriately, or attend school regularly (e.g.,
hearing impairment, visual impairment)?
o If Yes: What is this physical issue?
ƒ How is this physical issue impacting the child’s or youth’s
education?
ƒ How is this need being addressed?
Mental Health
ƒ Does the child or youth have any mental health issues that impair his or her
ability to learn, interact appropriately, or attend school regularly?
o If Yes: What is this mental health issue?
ƒ How is this mental health issue impacting the child’s or
youth’s education?
ƒ How is this need being addressed?
ƒ Is the child or youth currently being prescribed any psychotropic
medications?
o If Yes: Which medications have been prescribed?
ƒ Has the need for the child or youth to be taking this
medication been clearly and directly explained to him or her?
ƒ How will this medication affect the child’s or youth’s
educational experience?
National CASA E-Learning 11.05
Emotional Issues
ƒ Does the child or youth have any emotional issues that impair his or her
ability to learn, interact appropriately, or attend school regularly?
o If Yes: What is this emotional issue?
ƒ How is this emotional issue impacting the child’s or youth’s
education?
ƒ How is this need being addressed?
ƒ Is the child or youth experiencing any difficulty interacting with other
children or youth at school? (E.g., Does the child or youth have a network of
friends? Has he or she experienced any difficulty with bullying?)
o If Yes: What is being done to address this issue?
Special Education and Related Services Under IDEA and Section 504
ƒ If the child or youth has a physical, mental health, or emotional disability
that impacts learning, has this child or youth (birth to age 21) been
evaluated for Special Education/Section 504 eligibility and services?
o If No: Who will make a referral for evaluation or assessment?
o If Yes: What are the results of such an assessment?
o Have the assessment results been shared with the appropriate
individuals at the school?
ƒ Does the child or youth have an appointed surrogate pursuant to IDEA (e.g.,
child’s or youth’s birth parent, someone else meeting the IDEA definition of
parent, or an appointed surrogate parent)?
o If No: Who is the person that can best speak on behalf of the
educational needs of the child or youth?
o Has the court used its authority to appoint a surrogate for the child
or youth?
o Has the child’s or youth’s education decision-maker been informed
of all information in the assessment, and does that individual
understand the results?
ƒ Does this child or youth have an individualized education plan (IEP)?
o If Yes: Is the child’s or youth’s parent or caretaker cooperating in
giving IEP information to the appropriate stakeholders or signing
releases?
o Is this plan meeting the child’s or youth’s needs?
o Is the child’s or youth’s educational decision-maker fully
participating in developing the IEP, and do they agree with the
plan?
ƒ Does this child or youth have a Section 504 plan?
o If Yes: Is this plan meeting his or her needs?
o Is there an advocate for the child or youth participating in meetings
and development of this plan?
Extracurricular Activities and Talents
ƒ What are some identifiable areas in which the child or youth is excelling at
school?
ƒ Is this child or youth involved in any extracurricular activities?
o If Yes: Which activities is the child or youth involved in?
National CASA E-Learning 11.05
Are efforts being made to allow this child or youth to continue in his
or her extracurricular activities (e.g., provision of transportation,
additional equipment, etc.)?
ƒ Have any of the child’s or youth’s talents been identified?
o If Yes: What are these talents?
ƒ What efforts are being made to encourage the child or youth
to pursue these talents?
o
Transitioning
ƒ Does the youth have an independent living plan?
o If Yes: Did the youth participate in developing this plan?
ƒ Does this plan reflect the youth’s goals?
o If Yes: Does the plan include participation in Chafee independent
living services?
ƒ Does this plan include vocational or post-secondary
educational goals and preparation for the youth?
ƒ Is the youth receiving assistance in applying for post-secondary schooling
or vocational training?
ƒ Is the youth being provided with information and assistance in applying for
financial aid, including federally funded Educational and Training Vouchers
(see Chafee Foster Care Independence Program)?
ƒ If the youth has an IEP, does it address transition issues?
o If Yes: What does this transition plan entail?
o Did the youth participate in developing the transition plan?
o Is this transition plan coordinated with the youth’s independent
living plan?
Practice Tip: When appropriate, consider addressing these questions directly to
the children and youth.
From National Council of Juvenile and Family Court Judges, Casey Family
Programs, and TeamChild®, www.ncjfcj.org.
National CASA E-Learning 11.05
 TIPS FOR CHILD ADVOCATES
1.
Choose your issue. There will be many aspects of the child welfare system that are not
working most efficiently or effectively for the child. The child will also have multiple
issues/needs. Our recommendations may have to look at resolutions that are not ideal.
As the advocate, you must prioritize and weight what is MOST needed and important.
2.
Identify solutions. Never pose the problems without also having identified some
solutions to give the court recommendations about positive action that can be taken on
behalf of the child’s best interest.
3.
Identify supporters/resources. In identifying solutions, look for community resources
for the child, for the family, for potential caretakers. Look for adult connections, mentors,
support groups and extracurricular activities that will benefit the child.
4.
Develop a strategy. How will you advocate for positive outcomes for the child in their
current placement?, with regard to permanency?, within the child welfare system at the
local level?, within the state system? Continue to gather information with an open mind
that allows for recommendations and strategies to change.
5.
Frame your message. Communication with the court and other professionals is a key
element of advocacy. Using neutral, objective language will further recommendations.
Empathy and a non-defensive posture will demonstrate your trustworthiness. Write
effective court reports and give credible testimony.
6.
Educate. Build bridges with all service providers and take the opportunity to constantly
educate the system about the CASA role.
7.
Testify. Find the balance between assertive advocacy and open minded receptivity to
new information and an alternate plan. Speak with authority gained through the work
done. Also, offer to tell your story at a public hearing. The personal experiences of
constituents are very powerful in convincing government officials to make changes.
8.
Don't give up! Persistence, persistence, persistence. The child welfare system can be a
difficult arena in which to effect change. When a promising plan falls apart, it can be
hard to rally and start again. Remember, the child is depending on you and your strength
of conviction to pursue a hopeful future for them.
Advocating for Your Child: 25 Tips for Parents
Written by David Fassler, M.D.
Child & Adolescent Psychiatrist
According to the Surgeon General, 1 child in 5 experiences significant problems due to a
psychiatric disorder. The good news is that we can help many, if not most, of these
youngsters. The real tragedy is that so few, less than 1 in 3, are receiving the
comprehensive treatment they really need.
Children and adolescents with emotional and behavioral problems deserve access to the
best possible mental health care. Unfortunately, such services are often difficult to
obtain. Parents can help by being informed, involved and persistent advocates on behalf
of their children.
The following outline offers specific tips and suggestions, which parents may find useful
in such advocacy efforts.
Individual advocacy for your own child:
1. Get a comprehensive evaluation. Child psychiatric disorders are complex and at
times confusing. A full assessment often involves several visits. Effective treatment
depends on a careful and accurate diagnosis.
2. Insist on the best. Talk to physicians, therapists, guidance counselors and other
parents. Find out who in your community has the most experience and expertise in
evaluating and treating your child’s particular condition. Check the clinician’s
credentials carefully. Are they appropriately licensed or certified in your state? If he
or she is a physician, are they “Board Certified”? Push schools, insurance companies
and state agencies to provide the most appropriate and best possible services, not
merely services that are deemed sufficient or adequate.
3. Ask lots of questions about any diagnosis or proposed treatment. Encourage your
child to ask any questions he or she may have, as well. Remember that no one has all
the answers, and that there are few simple solutions for complex child psychiatric
disorders. In addition, all treatments have both risks and benefits. Make sure you and
your child understand the full range of treatment options available so you can make a
truly informed decision.
Fassler Resource
-1-
2003
4. Insist on care that is “family centered” and builds on your child’s strengths. Ask
about specific goals and objectives. How will you know if treatment is helping? If
your child’s problems persist or worsen, what options and alternatives are available?
5. Ask about comprehensive “wrap around” or individualized services, geared
specifically to the needs of your child and family. Are such services available in your
state or community? If not, why not?
6. Be prepared. One of the most important things you can do to help your child is to
keep all information, including past consultation and treatment reports, in an
organized place. Insist on receiving your own copies of all evaluations. Records can
easily be misplaced, delayed or even destroyed. Maintaining your own file with all
relevant information can help avoid unnecessary duplication of previous treatment
efforts.
7. Feel free to seek a second opinion. Any responsible mental health professional will
be glad to help with referrals or by sharing information. If you have questions about
your child’s diagnosis or the proposed course of treatment, by all means, arrange an
independent consultation with another clinician.
8. Help your child learn about their condition. Use books, pamphlets and the Internet.
Make sure the information is age appropriate. Answer questions with honest,
accurate and consistent information, but don’t overload children with more detail than
they want or need.
9. Know the details of your insurance policy, and learn about the laws governing
insurance in your state. For example, in some states, insurance companies must
provide access to a specialist, such as a child and adolescent psychiatrist, within a
certain distance from your home. If no such specialist is available as part of the
company’s “network”, you may be able to receive treatment from a provider of your
choice, with the insurance company responsible for full payment.
10. Work with the schools. Insist on access to appropriate mental health consultation
services. You can also suggest inservice training programs to enhance awareness
about child psychiatric disorders. Request copies of your child’s educational records,
including the results of any formal testing or other evaluations. Ask to be included in
any and all school meetings held to discuss your child.
11. Learn about the reimbursement and funding systems in your state. The more you
know, the better you can advocate on behalf of your child. How does Medicaid
work? Which services are covered and which are excluded? Is there a Medicaid
“waiver program” which allows increased flexibility based on the specific needs of
children and families? Is your child eligible? If not, why not? What other sources of
funding are potentially available?
Fassler Resource
-2-
2003
12. If necessary, use a lawyer. Learn about the local legal resources. Find out which
lawyers in your community are familiar with educational and mental health issues.
Talk to your local Protection and Advocacy agency or American Civil Liberties
Union for suggestions. Call the State Bar Association. Talk to other parents who are
lawyers or who have used lawyers. Consider a legal consultation to make sure you
are pursuing all appropriate avenues and options regarding services for your child.
Statewide advocacy for all children, including your own:
13. Become politically active. Meet with state senators and representatives. Question
candidates about their positions on access to necessary and appropriate mental health
services for children and families. Testify at hearings on state legislation and
budgets. Legislators are more likely to be influenced and persuaded by personal
stories than by data, statistics or the opinions of professionals.
14. Get to know the state insurance commissioner and healthcare “ombudsperson” or
consumer representative. Ask them to attend regular meetings with parent groups.
Let them know about your experiences.
15. Build coalitions and work with local advocacy and parent organizations such as the
National Alliance for the Mentally Ill (NAMI), the National Mental Health
Association (NMHA) and the Federation of Families for Children’s Mental Health .
Develop and publicize a common “Agenda for Children’s Mental Health”.
16. Teach children about advocacy. Invite them to become involved in advocacy
activities, where appropriate, but don’t force them to participate.
17. Develop a legislative strategy. If your state does not yet have parity legislation, put
this at the top of the agenda. Other “family protection” initiatives include:
•
•
•
•
•
access to an independent panel to review and potentially reverse insurance
company denials
consumer representation on community mental health center boards
adequate network provisions, which mandate timely and appropriate access to
specialists
adequate funding for school and community-based mental health services
interagency collaboration for children who are involved with more than one
system (i.e., child welfare, mental health, education and juvenile justice).
18. Seek bipartisan support. Mental illness affects families of all political persuasions.
Building a broad base of support has been a key to successful legislative initiatives,
both at the State and Federal levels.
19. Fight stigma. Develop an ongoing local education campaign that reiterates the key
messages:
Fassler Resource
-3-
2003
•
•
•
child psychiatric disorders are very real illnesses
they affect lots of kids and adolescents
fortunately, they are also treatable, especially if treatment begins early and is
individualized to the needs of each child and family.
20. Become involved with medical education. Meet with local medical students and
residents. Sensitize them to the issues and challenges families face when caring for a
child with emotional and behavioral problems.
21. Use the media. Write letters to the editor and/or op-ed pieces on child mental health
issues. Meet with local reporters covering health care topics. Suggest story ideas to
local TV stations.
22. Work with local professional organizations. Psychiatrists, psychologists, social
workers, psychiatric nurses, and mental health counselors are natural allies with a
common advocacy agenda. Coordinate efforts on issues such as parity, funding for
mental health services, managed care oversight, etc. Professional organizations may
also have access to resources, including funds for lobbying and/or public education
initiatives, from their national associations.
23. Talk to other parents. Seek out and join local parent support groups. If none exist,
consider starting one. Develop an email “listserv” to facilitate communication.
Circulate articles, information and suggestions about local resources.
24. Attend regional and national conferences of parent and advocacy organizations. Such
meetings provide information, ideas, camaraderie and support. Sharing experiences
with other parents is both helpful and empowering.
25. Don’t give up. Aim for and celebrate incremental victories and accomplishments.
Remember, advocacy is an ongoing process!
There’s no right or wrong way to be an advocate for your child. Advocacy efforts and
initiatives should be individualized to your state, community and the particular issues,
circumstances and needs within your family. Advocacy is also hard work. Even when
people want to help, and are willing to listen, it takes lots of time and energy to change
the system. But when it works, and it often does, the outcome is clearly worthwhile.
You really can make a difference, both for your own child, and ultimately for all children
who need and deserve access to appropriate and effective mental health treatment
services.
Fassler Resource
-4-
2003
Module II. Unit 4: Activity 2 - Quick Reference Grid on Information Sharing
Printer-friendly version
Print using your browser ‘Print’ button
<< Click the browser ‘Close’ button to move on
Can share all
information with Child
Welfare.
Can share information
related to educational
needs of child.
Dictated by Child Welfare licensing contracts and individual care plans.
This includes information necessary to provide adequate care for the
child.
National CASA E-Learning 11.05
Source: Field Guide for Information Sharing, WA State DSHS, WA State OSPI, Casey Family Programs, Treehouse, TeamChild, and Washington State CASA. 10/04
1. They can facilitate the sharing of information between other parties. In addition, they may disclose information to perform duties assigned by the court, such
as advocacy. When in doubt about what and with whom to share, discuss with your supervisor.
2. The best practice is for caregivers to get written consent for information sharing, signed by the caseworker assigned to the child. School staff and educators
are allowed to discuss with others their personal observations about a child.
3. “Caregiver” means person with whom the child lives as a result of placement by the court or Child Welfare.
Foster Placement,
Relative, Licensed
Caregiver (See 3.)
CASA/GAL volunteers may only disclose information to the court or to others allowed by court order. (See 1.)
CASA/GAL
Volunteer
Caregivers to get
written consent, signed
by caseworker
assigned to child.
School may discuss
personal observations.
(See 2.)
May discuss personal
observations. Schools
must release
educational records to
CASA/GAL volunteers.
Follow protocols for
requesting records.
Schools must release
educational records to
biological parents
unless a court order
limits parental access.
Enrolling district must
request student
records from the prior
district.
Schools can release
info to Child Welfare in
emergency, under
court order, subpoena,
and when child is in
dependent or shelter
care.
School Staff and
Educators
Retains control over information and can share with others, unless limited by a court order.
Caseworkers share
information with
caregivers necessary
for case planning.
Caseworkers share
everything with
CASA/GAL volunteers.
Caseworkers share all
information with very
few exceptions.
Caseworkers can share
information necessary
for case planning.
Caseworkers can share
all information within
their system.
Child Welfare
System
Parent or Legal
Custodian
Foster Placement,
Relative, Licensed
Caregiver
CASA/GAL
Volunteer
Parent or Legal
Custodian
School Staff and
Educators
Child Welfare
System
RECEIVERS OF INFORMATION
Review the following grid, which details what key givers and receivers of information can share. Some information may be specific to
Washington State laws and not applicable in other states. Ask your supervisor and note any questions you may have.
GIVERS OF INFORMATION